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ABSTRACT
This study examined the efficacy and feasibility of a brief telephone-delivered CBT-I
(TeleCBT-I) intervention in cancer patients compared to a control group. The study used a
randomized controlled trial design. The TeleCBT-I program consisted of a brief four-week CBTI program adapted for cancer patients. Patients completed assessment measures at pre-treatment,
post-treatment and one-month follow-up. Out of 184 patients screened, 39 were randomly
assigned, and 35 (TeleCBT-I, n = 19; Control, n = 16) completed pre- and post-treatment
measures and were included in the analyses. Compared to control group, the TeleCBT-I group
reported decreased insomnia severity symptoms (p < .014), improved sleep quality (p < .023),
and reduced dysfunctional beliefs about sleep (p = .039) at post-treatment with sustained
treatment effects at one-month follow-up. Sleep measures yielded large effect sizes (Hedges’ g,
0.84-2.7). Although the TeleCBT-I group indicated improvements in fatigue, general
functioning, physical well-being, functional well-being, and physical quality of life, effects at
follow-up were observed only for fatigue, functional well-being and physical quality of life. No
effects were found on depression at any of the time points. In terms of feasibility, TeleCBT-I
demonstrated high adherence, high homework completion and high overall satisfaction. These
results advance the empirical evidence of CBT-I in cancer patients and support the use of
telephone-delivered CBT-I to widely disseminate and implement among patients with cancer.
Key words: CBT-I, Insomnia, Cancer, Telephone, Telehealth
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CHAPTER ONE: INTRODUCTION
Insomnia is a common and debilitating condition that can affect cancer patients at any
time in the cancer continuum, from pre-diagnosis through long-term cancer survivorship. It is
estimated that up to 80% of cancer patients experience sleep disturbances, while up to 30% to
60% suffer from insomnia (Savard, Ivers, Savard, & Morin, 2015, 2016; Sharma et al., 2012). If
left untreated, insomnia is likely to become chronic, affecting the healing process and tumor
progression in cancer populations (Cash et al., 2015). Insomnia has been associated with a
number of negative physical and psychological consequences including: fatigue, pain,
depression, anxiety, diabetes, cardiovascular disease, poor quality of life, and even early
mortality (Palesh et al., 2017; Savard, Villa, Ivers, Simard, & Morin, 2009).
Considering that insomnia symptoms in cancer patients are often severe enough to
warrant treatment, the American College of Physicians (ACP, Qaseem et al., 2016) guidelines
recommend the screening and assessment of sleep complaints and treatment of insomnia during
routine cancer care. Furthermore, the ACP asserted that all adult patients with cancer and
comorbid insomnia symptoms receive cognitive behavioral therapy for insomnia (CBT-I) as the
first line of treatment. Mounting evidence has demonstrated that CBT-I is effective to treat
severe insomnia in adult populations, including cancer patients (Garland et al., 2014; Johnson et
al., 2016; Zachariae, Lyby, Ritterband, & O’Toole, 2016). Emerging evidence suggests that
CBT-I may also be beneficial in targeting other psychological outcomes in cancer patients, such
as depression, anxiety and fatigue, as well as, quality of life (Dirksen & Epstein, 2008; Johnson
et al., 2016).
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Despite its high prevalence and negative impact in health, tumor progression, daily
functioning, quality of life, and survival, insomnia is often under-recognized, under-diagnosed
and under-treated in oncology settings (Geiger-Brown et al., 2015; Innominato et al., 2009;
Johnson et al., 2016). Research has highlighted a number of challenges for cancer patients to
receive CBT-I in a timely fashion, including lack of awareness of CBT-I, low clinician priority
and referrals, limited trained providers, commute to treatment centers, and high cost and duration
CBT-I (Manber & Simpson, 2016; Siefert, Hong, Valcarce, & Berry, 2014; Sivertsen, Vedaa, &
Nordgreen, 2013). Another important challenge is that when treatment is offered, it generally
consists of sleep medication (Sandlund, Hetta, Nilsson, Ekstedt, & Westman, 2017; Siefert et al.,
2014), increasing the number of medications and side effects during cancer treatment.
Telehealth modalities have emerged as viable options to reduce barriers in care and
improve clinical health outcomes (Perle & Nierenberg, 2013). The number of telehealth
technologies and delivery formats is growing from live interactive video that allows providers to
provide remote intensive home care to mobile applications that patients use to access health
information and manage their health (Holmqvist, Vincent, & Walsh, 2014; Perle & Nierenberg,
2013). Given the empirical evidence demonstrating that CBT-I can help people sleep better,
there is a growing interest in its widespread dissemination and implementation with all
populations. Telehealth modalities can circumvent the challenges in disseminating CBT-I
without reducing its effectiveness. Indeed, promising research indicates that both internet-based
and telephone-delivered CBT-I programs are as effective as face-to-face individual and group
modalities in adult samples (Arnedt et al., 2013; Ritterband et al., 2017; Zachariae et al., 2016).
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Further research is needed to determine whether insomnia can be treated by delivering
CBT-I through telehealth. Considering the huge potential of telehealth in increasing access,
quality and efficiency in care (Chaet, Clearfield, Sabin, & Skimming, 2017), it is imperative to
test CBT-I with different telehealth formats to improve patient health, particularly for individuals
with chronic and debilitating conditions, such as cancer. Telehealth technologies may reduce
barriers to disseminate and implement CBT-I in oncology settings. For example, patients can
have access to CBT-I information and psychotherapy from the convenience of their home or
work office, eliminating practical barriers, such as transportation issues, child care, as well as
reduce overall cost and time invested in accessing care (Brenes, Ingram, & Danhauer, 2011;
Chaet et al., 2017).
Although there is abundant interest in pursuing a widespread dissemination of CBT-I
utilizing telehealth technologies, there is a lag in research with cancer patients. Telehealth
research with CBT-I have largely focused on internet-based and mobile applications, despite
telephone communication still being the most convenient, cost-effective, and ever-present form
of communication in the United States and worldwide (Brenes et al., 2011).
To date, no research has examined CBT-I delivered through telephone communication
with cancer patients. The present study adapted and tested a 4-week CBT-I program delivered
via telephone to cancer patients. The main objectives were to test the efficacy and feasibility of a
brief telephone-delivered CBT-I (TeleCBT-I) program in cancer patients. In this randomized
controlled study, the effects of TeleCBT-I were compared to a treatment-as-usual control group.
TeleCBT-I treatment gains over time were examined at one-month follow-up. The feasibility of
telephone-delivered CBT-I in cancer patients was evaluated over the course of four weeks.
3

CHAPTER TWO: LITERATURE REVIEW
Insomnia
Insomnia is characterized by subjective complaints about difficulty initiating sleep,
difficulty maintaining sleep, waking up too early in the morning or experiencing non-restorative
or poor quality of sleep (Qaseem et al., 2016; Roth, 2007). As per the International Guidelines
of Sleep Disorders (Thorpy, 2017), both reduced sleep time and impaired daytime functioning
are important aspects in the diagnosis of insomnia disorder. The clinical diagnosis of chronic
insomnia disorder according to the American Psychiatric Association’s Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5) and the International Classification of Sleep
Disorders, Third Edition, specify that symptoms cannot be associated with another sleep or
medical disorder, must cause clinically significant functional impairment and be present at least
three days in a week and for at least three months (American Psychiatric Association, 2013;
Thorpy, 2017).
The prevalence of insomnia is higher among women than men and tends to increase as
people age with a sharp spike among adults aged 55-64 years old as observed in the National
Health Interview Survey from 2002-2012 (Ford, Cunningham, Giles, & Croft, 2015). The
development and progress of insomnia seems to be determined by predisposing, precipitating,
and perpetuating factors (Bastien, Morin, Ouellet, Blais, & Bouchard, 2004). Predisposing
factors may include a person’s genetics, gender, age, family history, trait anxiety, and
predisposition to rumination (Bush et al., 2016; Hammerschlag et al., 2017; Harvey, Gehrman, &
Espie, 2014), while precipitating factors consist of psychological and physical dysfunctions and
4

environmental, family and work-related circumstances. In cancer patients precipitating factors
may include diagnosis of cancer, severity of disease, cancer treatment, side effects of cancer
treatment, menopausal symptoms including pain or fatigue, and medications (Bastien et al.,
2004; Savard et al., 2009). Perpetuating behavioral factors include long-term use of medications
or use of inappropriate medications, and dysfunctional coping (i.e., inaccurate appraisal of sleep
difficulties and quality) (Tremblay, Savard, & Ivers, 2009).
The American Academy of Sleep Medicine and Sleep Research Society consensus
recommends seven or more hours of sleep to promote optimal health in adults. Aside from
increasing the number of hours of sleep, the goal of treatment for insomnia is to improve sleep
quality, as well as, to reduce day time impairment caused by the disorder (Schutte-Rodin, Broch,
Buysse, Dorsey, & Sateia, 2008). Treatment options for insomnia include psychological therapy,
pharmacologic therapy, or a combination of both (Qaseem et al., 2016). Psychological therapy
options include CBT-I, multicomponent behavioral therapy or brief behavioral therapy for
insomnia, and other interventions such as stimulus control, relaxation strategies, and sleep
restriction. Among these interventions, CBT-I is considered the gold standard treatment for
insomnia as per clinical guidelines and practice parameters of the American Academy of Sleep
Medicine and the American College of Physicians (Qaseem et al., 2016; Sateia, Buysse, Krystal,
Neubauer, & Heald, 2017).

Cognitive-Behavior Therapy for Insomnia (CBT-I)
The evidence that CBT-I is an effective treatment for insomnia and produces enduring
effects lasting beyond treatment has been established. CBT-I was designed to improve sleep
5

disturbance by addressing psychological and behavioral factors involved in the development and
maintenance of insomnia (Morin et al., 2015; Siebern & Manber, 2011). CBT-I combines
components of cognitive and behavioral therapies. Cognitive therapy addresses dysfunctional
beliefs and thoughts about sleep, while behavioral therapy targets behaviors and habits that do
not promote sleep and are not conducive to healthy sleep patterns (Morin, 2010). The major
components in CBT-I include: cognitive restructuring (CR), stimulus control (SC), sleep
restriction (SR), sleep hygiene (SH), and relaxation techniques (RT) to improve sleep outcomes
(Siebern & Manber, 2011; Annemieke van Straten et al., 2018). CBT-I is often provided
individually or in group formats and traditionally is delivered during the course of eight to
twelve sessions (Manber & Simpson, 2016; Siebern & Manber, 2011).
Accumulative evidence including randomized controlled trials, meta-analyses (Koffel,
Koffel, & Gehrman, 2015; Sandlund et al., 2017; Trauer, Qian, Doyle, Rajaratnam, &
Cunnington, 2015; Annemieke van Straten et al., 2018) and systematic reviews (Cunningham &
Shapiro, 2018; Mitchell et al., 2014) established that CBT-I is an effective treatment for adults
with chronic insomnia with clinically and statistically significant effect sizes. Indeed, a recent
review and meta-analysis assessed the efficacy of face-to-face CBT-I on 20 randomized
controlled trials and demonstrated that CBT-I at post-treatment improved sleep time by 7.61 (CI,
-.51 to 15.74) minutes and sleep efficiency by 9.91% (CI, 8.09% to 11.73%) with sustained gains
over time (Trauer et al., 2015).
Furthermore, emerging evidence supports the use of CBT-I in adults with comorbid
medical or psychiatric conditions (Geiger-Brown et al., 2015). Although the efficacy and
effectiveness of CBT-I is well-established, CBT-I is under-utilized in medical settings.
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Therefore, researchers have called attention to the need of facilitating the dissemination and
implementation of CBT-I to all populations, including cancer patients who may experience
additional barriers to care. Moreover, current trends in the literature suggest reducing the length
of CBT-I and establishing evidence for other forms of delivery in order to reach a greater number
of patients (Morin, 2010; Sandlund et al., 2017; Zhou, Partridge, & Recklitis, 2017).

CBT-I for Cancer Patients
Compared to pharmacological treatment, CBT-I has been associated with substantial and
sustained clinical benefits among cancer patients (Heckler et al., 2016; Peoples et al., 2017). A
recent systematic review of CBT-I with patients of different types of cancers reviewed 12 trials
(4 controlled and 6 uncontrolled) and found that CBT-I was associated with statistically and
clinically significant improvements in subjective sleep outcomes (Garland et al., 2014).
Additionally, this review demonstrated that CBT-I had positive effects in mood, fatigue, and
overall quality of life. CBT-I was also successfully delivered through a variety of treatment
modalities (e.g., self-help, videoconferencing and individual and group therapy). Moreover,
Garland et al., (2014) concluded that studies with homogeneous cancer groups did not have a
treatment advantage over studies that included mixed groups of cancer patients, suggesting that
treatment effects may be similar irrespective of cancer stage and tumor location. Nonetheless,
most research has been conducted with breast cancer patients, highlighting the need to
investigate the effect of CBT-I concurrent with a broad range of cancer diagnoses. For example,
in a recent meta-analysis of randomized controlled trials of CBT-I in cancer patients, three of the
eight studies evaluated included patients with mixed cancer diagnoses (Johnson et al., 2016)
7

CBT-I for Breast Cancer Patients (BCS)
CBT-I is an efficacious treatment for people with comorbid breast cancer and insomnia.
Using the main components of the CBT-I (i.e., SC, RT, SH, and CR), researchers have examined
CBT-I delivered in individual, group and self-administered modalities with breast cancer
patients. Studies included both uncontrolled and controlled trials. A multiple baseline single
subject study evaluated CBT-I and fatigue management in women with breast cancer stages I-III
(N =10). This study found that although sleep severity was significantly decreased at six-month
follow-up, there was no significant decline in depression, anxiety, fatigue, or quality of life
(Quesnel, Savard, Simard, Ivers, & Morin, 2003). Another study found that women with breast
cancer stage I-III (N = 11) who participated in a self-administrated program of CBT-I reported
significantly reduced insomnia severity, depression, and increased quality of life, but no
significant reduction in anxiety and depression at three-month follow-up (Savard, Villa, Simard,
Ivers, & Morin, 2011). These findings provide mixed evidence that CBT-I may have an effect on
other psychological variables such as depression, anxiety, fatigue, and quality of life, and
therefore more research is needed.
Most controlled trials showed positive outcomes associated with CBT-I in BCS. Dirksen
& Epstein (2008) tested the efficacy of a multicomponent CBT-I in BCS compared to a control
group that received sleep education and information on sleep hygiene. The study included 72
women who were at least three-month post-primary cancer treatment. Both groups sustained
significant time effects for sleep onset latency, wake after sleep onset, time in bed, sleep
efficiency and sleep quality after treatment. Although this study may have minimized the effect
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of CBT-I over a psychoeducational sleep approach, it also indicates that low intensity sleep
intervention may have a significant impact on BCS.
Other controlled trials have demonstrated that CBT-I reduced insomnia severity,
depression, anxiety, and fatigue, and increased quality of life on women with breast cancer
stages I-III (Barsevick et al., 2010; Casault, Savard, Ivers, & Savard, 2015; Mitchell, Gehrman,
Perlis, & Umscheid, 2012; Savard et al., 2011). Similar treatment effects have been found even
when CBT-I is delivered during chemotherapy treatment. Mitchell et al., (2009) examined the
effects of individual CBT-I on a group of 219 women who were randomly assigned before
chemotherapy treatment to CBT-I group or a health-eating control condition. Differences were
found between groups in sleep quality and sleep efficiency at 30-days posttreatment, but only
improved sleep quality was sustained at one-year follow-up. Together, these findings support
that CBT-I is effective at improving insomnia symptoms in BCS. Additionally, these findings
also highlight the need to investigate whether CBT-I is also helpful at targeting other
psychological symptoms comorbid with insomnia and faced throughout the cancer treatment
continuum.

Telehealth
Telehealth utilizes a broad range of electronic information and telecommunication
technologies to provide long-distance clinical health care (Weinstein et al., 2014). Technologies
include a wide range of options from low-cost applications such as telephone, video or home
computers to more complex ones, such as telesurgery (Chaet et al., 2017; Porzsolt & Kaplan,
2006). The terms telehealth and telemedicine are often used interchangeably even by leading
9

telehealth and telemedicine organizations (American Telemedicine Association, 2016). The main
difference is in the range of services provided, as telemedicine concerns with the delivery of
diagnostic and clinical services, while telehealth extends to a broader range of services including
patient care, self-management, and education (American Telemedicine Association, 2016).

Telehealth and CBT-I.
Given that the effectiveness of CBT-I in cancer patients is well documented, the next
scientific venture is to make CBT-I more accessible and cost-effective for all populations.
Telehealth supports novel applications to delivering CBT-I to individuals who would not
otherwise have access to treatment.
Although limited, emerging research support the use of telehealth technologies to
disseminate CBT-I. Growing evidence favors the use of internet-based applications of CBT-I.
Several clinical trials demonstrated that web-based CBT-I delivered by an automated virtual
therapist (Espie et al., 2008) or guided by a therapist (Blom et al., 2015; Kaldo et al., 2015; van
Straten et al., 2014), as well as, self-help or self-administered interventions (Connelly, Gee, &
Walsh, 2007; Lancee, van den Bout, van Straten, & Spoormaker, 2012; Ritterband et al., 2009;
Ström, Pettersson, & Andersson, 2004). For example, a recent meta-analysis included eleven
randomized controlled trials published from 2004 to 2015 and examined 1,460 participants,
documenting that CBT-I delivered via telehealth improved insomnia symptoms at post-treatment
with effect sizes (Hedges’ g) for insomnia severity of 1.09, 0.58 for sleep efficiency, 0.49 for
sleep quality and .021 for number of nocturnal awakenings (Zachariae et al., 2016). Treatment
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outcomes were comparable with those found in face-to-face CBT-I interventions and were
sustained at one-month to twelve-month follow-up.
Research on telehealth and CBT-I is fairly new and even more so with cancer patients.
Out of the eleven studies included in a recent meta-analysis, only one was conducted with cancer
patients (Zachariae et al., 2016). The sample included 28 cancer patients randomized to either
internet-based CBT-I or waitlist control group (Ritterband et al., 2012). Findings indicated that
participants in the internet-based CBT-I group showed improvements in insomnia symptoms at
post-treatment compared to control group. Although encouraging, this evidence highlights the
need to further investigate the efficacy of CBT-I delivered via telehealth modalities to cancer
patients.
In this review of the literature only six empirical studies of CBT-I using some form of
telehealth with cancer patient were found (Epstein & Dirksen, 2007; Ritterband et al., 2012;
Savard, Ivers, Savard, & Morin, 2014; Savard et al., 2016, 2011; Zhou, Vrooman, Manley,
Crabtree, & Recklitis, 2017). Table 1 presents a summary of the six studies. These studies
examined a wide range of telehealth modalities, including: internet-based, self-administered
animated videos, video conference, and a combination of group therapy with individual
telephone calls, providing preliminary evidence for the use of telehealth to deliver CBT-I in
cancer populations. Although promising, more research is needed to determine which telehealth
format is more conducive to disseminate CBT-I without affecting its effectiveness in treating
insomnia in cancer patients. Furthermore, although one study included telephone calls (Dirksen
& Epstein, 2008), the telephone calls served as supplement to the actual group therapy and thus it
does not constitute a true use of telehealth in providing CBT-I. These findings also highlight the
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need to investigate whether telephone-delivered CBT-I is efficacious and feasible in cancer
populations.

Telephone-delivered CBT-I
Telehealth application such as individual telephone calls is far more cost-effective and
accessible to deliver than traditional face-to-face interventions and even more so than other
forms of telehealth, such as video-conferencing and internet-based therapy (Brenes et al., 2011).
Two studies have examined the use of telephone-delivered CBT-I. Bastien et al., (2004)
compared face-to-face individual therapy, face-to-face group therapy and telephone consultations
with 45 adults with insomnia. This study found that CBT-I was effective in reducing insomnia
symptoms across treatment modalities and at six-month follow-up. Another study compared
CBT-I delivered by telephone (n = 15) to passive control group (n = 15). The control group
received an informational brochure (Arnedt et al., 2013). Both groups reported significant effect
in all sleep measures. It is possible that the content of the brochure included some aspects of
CBT-I, thus making it more therapeutic than intended. These findings suggest that some aspects
of CBT-I could be beneficial as a stand-along intervention and potentially that a full dose of
CBT-I is not warranted for all populations. Future research should explore the effect of
telephone-delivered CBT-I compared to a control group, particularly to non-treatment control or
wait-list control in order to discern whether changes between groups are greater for CBT-I
delivered by telephone than a pure non-treatment group.
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Telephone-delivered Interventions for Cancer Patients
Telehealth in the form of individual telephone calls or telephone consultations has been
associated with positive outcomes and high levels of satisfaction among cancer patients receiving
cancer genetic counseling (Zilliacus et al., 2010). Another study documented the use of a nurseled telephone-based intervention to support cancer patients receiving oral chemotherapy
(Barsevick et al., 2010). Although this intervention was not randomized, it provides exploratory
evidence of telephone-based services for cancer populations. A recent study suggests that
telephone-delivered cognitive behavioral therapy was comparable to face-to-face CBT for
reducing anxiety and depression and improving coping skills in cancer patients (Watson, White,
Lynch, & Mohammed, 2017). Furthermore, problem-solving interventions delivered via
telephone have been effective in cancer patients as well (Watson et al., 2013).
In sum, the literature supports the use of CBT-I as the first-line of treatment for insomnia
in cancer patients and encourages the use of telehealth to disseminate and implement CBT-I to
all populations. Thus, given the proliferation of telehealth technologies and the growing evidence
favoring the delivery of CBT-I through telehealth, it is imperative to examine which telehealth
modality would be most efficacious and feasible in cancer populations. To our knowledge, no
study to date has evaluated the efficacy of telephone-delivered CBT-I in cancer patients.
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Table 1.
Summary of Studies Investigating Telehealth and CBT-I in Cancer Patients
Study
Ritterband et
al., 2012

Sample
Characteristics
Males and
Females;
Mean 56.7

Allocation

Diagnosis/
Stage

Type of
Telehealth

Treatment
Components

Sessions
6 session over 9
weeks (45-60 min)

CBT-I = 14,
WLC = 14

State I-IV

Internet-based

SC, SR, SH,
CR

6 videos, weekly
(60 minutes) + 1
booklet
6 videos, weekly,
(60 minutes) + 6
booklet; 6
individual sessions
(50-minutes)

Follow-up
None

Savard et al.,
2011

Females; Mean
51.5 (37-74)

VCBT-I = 11

Breast
Stage I-III

Self-administered
animated DVD +
Booklet

SC, SR, CR,
SH, RP

Savard et al.,
2014

Females; Mean
54.4 (18-75)

Individual = 81,
Video-based =
80, Control = 81

Breast;
Stages 0-III

Self-administered
animated DVD +
Booklet

SC, SR, CR,
SH

Savard et al.,
2016

Females; Mean
54.4 (18-75)

Individual = 81,
Video-based =
80, Control = 81

Stages 0-III

Video-based
(animated 60minute video + 6
booklets)

SC, SR, CR,
SH

6 sessions; 6 weeks
(60 minutes)

3-, 6-, and
12-month

Zhou et al.,
2017

Males and
females; Mean
28.1 (15-40)

In-person = 6,
Videoconference
=4

Leukemia/
Lymphoma,
Solid Tumor

Videoconference
(Sessions 2 & 3)

SR, SC, SH,
CR

3 sessions
(60 minutes)

2- month

3-month

None

4 weekly groups
and 2 weekly
Combined group
Epstein &
Females; Mean
CBT-I = 34
Breast Stages
SR, SC, SE,
telephone sessions
with 2 phone
None
Dirksen, 2007
57.1 (29-74)
Control = 38
I-III
SH
(60-120-minutes
conversations
group & 15-30
minutes telephone)
Note. Abbreviations: CBT-I, cognitive behavioral therapy for insomnia; WLC, wait list control; SC, stimulus control; SR, sleep restriction; SH, sleep
hygiene; CR, cognitive restructuring; VCBT-I, video-based CBT-I; RP, relapse prevention; SE, sleep education.

14

Current Study
Based on the existing scientific knowledge, technological advance and practice
patterns, the current study aims to contribute to the growing literature on the use of telehealth
to effectively disseminate CBT-I to cancer patients. The goals of the study are to test the
efficacy and feasibility of a brief telephone-delivered CBT-I program among patients with
different types of cancer diagnoses. Although the effectiveness of CBT-I has been established
(Manber & Simpson, 2016; Morin et al., 2015; Siebern & Manber, 2011) and its effectiveness
in cancer patients is well-documented by previous studies (Dirksen & Epstein, 2008; Espie et
al., 2008; Garland, Rouleau, Campbell, Samuels, & Carlson, 2015; Howell et al., 2014), its
efficacy using telehealth has yet to be established. In order to build the strongest empirical
evidence, this study was undertaken as a randomized controlled trial comparing telephonedelivered CBT-I (TeleCBT-I) to a treatment-as-usual control group and is reported in
accordance with the CONSORT statement for non-pharmacological trials (Boutron et al.,
2017).
As noted in the literature, the issue is no longer whether CBT-I is effective, but how to
effectively disseminate it. Despite the evidence of CBT-I in reducing insomnia among cancer
patients, CBT-I remains underutilized and largely inaccessible to cancer patients. Research
demonstrated that insomnia is not routinely screened, assessed or diagnosed during the cancer
treatment trajectory, and when diagnosed cancer patients are more likely to be offered
medication treatment instead of a referral to non-pharmacological treatments (Siefert et al.,
2014). Unfortunately, those who are referred to non-pharmacological treatment, such as CBT-I
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face substantial challenges to access treatment in a timely fashion. For example, CBT-I may be
delayed due to limited availability of trained providers, transportation costs, treatment duration,
and cost of face-to-face treatment sessions (Morin, 2010; Siefert et al., 2014; Sivertsen et al.,
2013). Aside from these common barriers, cancer patients face additional challenges to access
CBT-I. For example, medical complications related to cancer treatment may limit their ability
to engage in additional treatment services outside of their home or hospital. Furthermore,
cancer patients may have exhausted social, financial, and work-related resources in their
extensive cancer care.
Given the barriers to delivering CBT-I to cancer patients, there is an urgent need to
investigate alternative treatment delivery options to improve CBT-I dissemination to cancer
patients. To date, only three studies have evaluated the use of telephone-delivered CBT-I in
adult populations and found positive clinical outcomes (Arnedt et al., 2013; Bastien et al.,
2004; Holmqvist et al., 2014). However, no study has tested the use of telephone-delivered
CBT-I in cancer patients.
Using a randomized controlled trial design, this study examined the efficacy and
feasibility of a brief telephone-delivered CBT-I program in cancer patients compared to a
treatment-as-usual control group. For the purpose of this study, a four-week CBT-I program
was adapted for cancer patients. The main aims were twofold: (1) to test the efficacy of
TeleCBT-I in reducing insomnia symptoms at post-treatment and one-month follow-up, and
(2) to evaluate the feasibility of TeleCBT-I in cancer patients. Based on preliminary evidence
suggesting that CBT-I may improve other comorbid psychological symptoms, the study also
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examined whether TeleCBT-I had an effect on fatigue, depression, anxiety, general
functioning, and quality of life.

The primary hypotheses were:
(1) Compared to control group, cancer patients in the TeleCBT-I group would show
improvements in insomnia severity, quality of sleep, and beliefs about sleep at
post-treatment.

(2) Compared to control group, TeleCBT-I group would report improvements in all
sleep measures at one-month follow.

(3) Those in the TeleCBT-I group would be actively engaged by attending the four
treatment sessions over the telephone and completing their homework daily or
almost daily.

The secondary hypothesis was:
(4) Compared to control group, TeleCBT-I group would show beneficial changes in
fatigue, anxiety, depression, general functioning and quality of life.
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CHAPTER THREE: RESEARCH DESIGN AND METHODOLOGY
Participants

Eligibility Criteria
Patients met criteria to participate in the study if they were 18 years or older, were
receiving medical treatment at Orlando Health UF Health Cancer Center (OH-UFCC), had a
cancer diagnosis and concurrent diagnosis of insomnia. Insomnia diagnosis was assessed with
the Structured Clinical Interview for DSM-5 Sleep Disorders Module (Taylor et al., 2018) and
the Insomnia Severity Index (ISI) with a score of eight or higher (Buysse, Ancoli-Israel,
Edinger, Lichstein, & Morin, 2006). Additional inclusion criteria were the ability to speak and
read English. Exclusion criteria were other diagnosed sleep disorders (e.g., narcolepsy), as well
as, other untreated pre-existing sleep disorders (e.g., sleep apnea), severe psychiatric diagnosis
(e.g., schizophrenia), cognitive impairment or dementia, or neurological disorder, and active
psychotic symptoms, suicidal ideation, intention or plan or substance use. Additionally,
subjects were excluded if unable to attend at least three of the four TeleCBT-I sessions.

Recruitment
This study was reviewed and approved by the Orlando Regional Medical Center
Internal Review Board and the University of Central Florida Internal Review Board. (See
Appendix A). Participants were recruited from the patient population at Orlando Health UF
Health Cancer Center (OH-UFCC) clinics. Recruitment flyers were displayed throughout the
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different OH-UFCC clinics and distributed at group activities provided by the OH-UFCC’s
Integrative Medicine Department (See Appendix B). Patients were identified and referred by
their medical providers if presenting with insomnia related complaints. Additionally, patients
were able to self-refer to participate in the study. Patients were first screened by telephone to
determine study eligibility before enrollment. Providers were informed about the study and
recruitment procedures during staff meetings, didactic or grand rounds presentations.
Furthermore, an information letter was disseminated every three to four months to oncology
physicians and providers explaining the study aims, eligibility criteria and recruitment
procedures (See Appendix C).
Among the patients that were approached (n = 184), 132 were deemed eligible to
participate in the telephone screening. The telephone screening identified 53 patients that met
criteria and were invited to complete a diagnostic clinical interview. A total of 47 diagnostic
clinical interviews were completed and 39 patients were randomized to either the TeleCBT-I or
control groups. Appendix D exhibits patient recruitment and study follow chart.

Sample Size Justification
A priori power analyses were performed to estimate the number of participants needed
to test the primary hypotheses. Power analyses were computed with G Power 3.1.9.2. Previous
research on telephone-delivered CBT-I reported large effect sizes ranging from .80 to 2.5. The
number of participants needed to determine whether there is a mean difference between the
CBT-I and the control group was computed with a significance level of 5%, statistical power of
80%, and a to-be-detected population effect size of .80 as reported by Arnedt et al., 2015. The
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estimated total sample needed was 42 (n = 21 each group). Then, the necessary sample size to
test whether there are mean differences between groups for time and group x time interactions
was evaluated with the same statistical parameters as above. However, to capture a wider range
effect size, a medium effect size for analyses of variance was computed (.25) (Cohen, 1992).
The estimated total sample was 28 (n = 14 each group). Thus, ascertaining treatment effects
with statistical confidence should require at least 14 participants in each group. As with any
study, the larger the sample size, the higher the confidence in its results.

Telephone Screening
Appendix E presents the script and screening used to identify potential study
participants over the telephone. Details about the study were further explained during the
telephone screening. If interested in participating in the study, patients were asked to complete
the Sleep Disorders Questionnaire (SDQ) over the telephone. The SDQ measures the potential
of meeting clinical criteria for insomnia. Those screened positively for a potential insomnia
diagnosis were deemed pre-qualified for the study and were invited to complete an in-person
diagnostic interview at OH-UFCC. Those who were not interested in participating in the study
after pre-qualification were given the option to receive the same CBT-I program in person.
None of the patients opted to receive the CBT-I in person.
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Study Design and Procedures

Study Design
This is a two-group (intervention and control), prospective, randomized, single-center
experimental design study. This study is part of a larger study with multiple follow-up
assessments. Patients received four treatment sessions of TeleCBT-I provided by three trained
graduate-level clinicians supervised by a licensed psychologist. Patients had the option to
receive a booster session after completing the last treatment session, an option taken by only
two patients. Sessions were between 45-75 minutes each. In most cases, the first session, which
included psychoeducation and information about the structure and procedures of the study, and
the last session, which explained treatment expectations, follow-up procedures and post
assessment took longer. Each patient completed measures at screening, pre-treatment, posttreatment and at one-month follow-up. The Consolidated Standards of Reporting Trails
(CONSORT) and the recommendations for standard research and assessment of insomnia were
applied (Buysse et al., 2006; Moher et al., 2010). Appendix F shows RCT procedures flow
charts.

Study Setting
This study was conducted at Orlando Health UF Health Cancer Center (OH-UFCC)
through its Integrative Medicine Department in Orlando, Florida. OH-UFCC is a statedesignated Cancer Center of Excellence, which is one of the most prestigious state recognitions
provided by the State Surgeon General and Secretary of Health to cancer care entities (Florida
21

Department of Health, Office of Communications, 2015). Its state-of-the-art facilities serve
over 80,000 patients annually and offer inpatient and outpatient services throughout locations
at Orlando and Gainesville. For the purpose of this study, enrollment was limited to patients
receiving treatment in Orlando, Florida.

Diagnostic Clinical Interview
During the diagnostic clinical interview patients provided consent to participate in the
study, and completed a structured clinical interview, pre-treatment measures and an intake and
demographic questionnaire. Appendix G presents the intake and demographic questionnaire.
Part of the consent process included obtaining medical clearance from patients’ oncologist or
medical provider. Thus, patients were asked to sign a medical clearance form, which was then
used to collect the medical approval and clearance to participate in the study (See Appendix
H).
The Structured Clinical Interview for DSM-5 Sleep Disorders Module was used to
diagnosed insomnia disorder and rule out other sleep disorders. Only those who met DSM-5
criteria for insomnia disorder were enrolled in the study. Those assigned to the TeleCBT-I
group were asked to complete a sleep diary for a minimum of two consecutive weeks prior to
treatment. Patients were given the option to discontinue study participation at any time.

Randomization and Allocation
Eligible patients were randomized to either TeleCBT-I or control group. The RAND
function of Microsoft Excel (Microsoft, version 2016) was used to generate unrestricted
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randomly permutated codes prior to enrollment. Unrestricted or simple randomization
assignment is similar to repeated coin tossing, and as a result, unequal group size is expected.
In fact, it has been argued that forcing equal group size in simple randomized trials is merely
cosmetic than scientifically (Schulz & Grimes, 2002). Thus, moderate discrepancy between
groups was expected in accord to the essence of randomness as recommended by Schulz &
Grimes (2002). Sealed envelopes were used to reveal allocation during the diagnostic
interview. Initially, patients were randomized to three conditions (Group TeleCBT-I,
Individual TeleCBT-I, and control group), but it was thereafter discontinued and the four
patients that were assigned to the group TeleCBT-I format were re-assigned to individual
TeleCBT-I.

Brief TeleCBT-I Program
After a comprehensive review of the literature, the brief TeleCBT-I program was
developed using a multicomponent approach as tested in most clinical trials and clinical
practices (Siebern & Manber, 2011). TeleCBT-I incorporated the most frequently used
components of CBT-I: 1) sleep education, 2) sleep hygiene, 3) stimulus control, 4) sleep
restriction, 5) cognitive restructuring, and 6) relaxation training (Manber & Simpson, 2016).
Content components were condensed and separated into four sessions, instead of the usual
eight to twelve CBT-I sessions. The resulting TeleCBT-I program consisted of four treatment
sessions delivered once per week over the course of four weeks.
TeleCBT-I included a patient manual and workbook that was mailed to patients after
completing the sleep diary and prior to initiating treatment. The manual was developed based
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on existing CBT-I protocols (Edinger & Carney, 2008, 2015; Manber & Simpson, 2016).
Additionally, it was tailored to address the unique needs of cancer patients by including
scientific knowledge of how poor sleep affects patients with cancer and cancer survivors.
Relevant information about patients’ experiences with cancer treatment and poor sleep were
also included throughout the different components. For example, cognitive restructuring
included examples of dysfunctional thoughts of how lack of sleep would affect their health and
cancer treatment. Table 2 presents an outline of the brief TeleCBT-I program components.
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Table 2.
TeleCBT-I Program Outline
Week
1









Outline
Welcoming and participant introductions
Overview of TeleCBT-I program and study protocol
Sleep education
Sleep hygiene, part 1
Stimulus control
Review sleep diary
Set goals and provide week assignment

2









Review of session 1 and homework
Review sleep diary
Sleep hygiene, part 2
Relaxation techniques
Sleep restriction
Development of new sleep schedule
Set goals and provide week assignment

3







Review of session 2 and homework
Review sleep diary
Adjust sleep schedule and calculate sleep efficiency
Cognitive restructuring
Set goals and provide week assignment

4









Review of sessions 1 - 3 and homework
Review of sleep diary
Review and adjust sleep schedule as needed
Discuss sleep medications side effects and tapering strategy
Relapse prevention
Complete post-treatment measures
Review follow-up plan and schedule
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Control Group
Patients allocated to the control group continued receiving treatment as usual. Patients
were told that they needed to complete two sets of measures before beginning TeleCBT-I.
Patients completed post-treatment and follow-up measures over the telephone at four- and
eight-weeks, respectively. Patients were also given the choice to complete their measures in
person or by mail. After completing the one-month follow-up measures, patients allocated to
the control group were offered TeleCBT-I following the same procedures as those in the
TeleCBT-I group.

Telephone Equipment and Protocol
The TeleCBT-I program was provided over the telephone using the OH-UFCC
telephone service. Patients used their personal phones to participate in the sessions with no
additional cost to them. Patients were asked to allot 60 to 90 minutes for the telephonedelivered CBT-I sessions. Safety measures were taken following telehealth guidelines
recommendations. Specifically, patients provided information of current location and another
telephone number to contact them in the event the telephone call was disconnected. Patients
were also asked to ensure privacy by taking the telephone call from a private space (e.g., nonshared space within their home or office), and avoiding using the speaker mode if there is a
possibility that another person could hear them.
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Measures

Screening
Sleep Disorders Questionnaire (SDQ; Douglass et al., 1994). The SDQ includes 18
items designed to identify those who: 1) meet criteria for a sleep disorder, 2) report problems
with sleep and 3) do not report sleep problems. Patients were asked to answer each question
using a Likert scale ranging from 1 (Never) to 5 (Always). The SDQ has a sensitivity of 95%
and specificity of 87% for insomnia. The SDQ has been used studies with cancer patients, but
reliability scores were not reported (Garland, Carlson, Antle, Samuels, & Campbell, 2011).

Structured Clinical Interview
The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition Sleep Disorders (SCISD; Taylor et al., 2018). The SCISD is a brief
clinician administered clinical interview that includes 20 to 51 questions and takes 10 to 20
minutes to administer. The interview assesses nine major sleep disorders, including insomnia
as specified in the DSM-5. Taylor et al., (2018) reported the SCISD had an excellent interrater
reliability for insomnia (1.0).

Sleep Measures
Insomnia Severity Index (ISI; Morin, 1993). The ISI is a brief measure of subjective
sleep complaints and associated distress. The ISI examines global severity of insomnia based
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on difficulty initiating or maintain sleep, and degree of dissatisfaction and daytime impairment
associated with insomnia. It is comprised of seven items rated on 5-point Likert scale ranging
from 0 (None) to 4 (Very Severe). Higher scores indicate greater impairment and a score of 8
indicates possible insomnia. The ISI has been shown to have high internal consistency
(Cronbach’s alpha = .90-.91) (Morin, Belleville, Bélanger, & Ivers, 2011) and has been
validated for use with cancer patients (Cronbach’s alpha = .90) (M. H. Savard, Savard, Simard,
& Ivers, 2005). The ISI has also been found to be sensitive to therapeutic changes (Morin,
Beaulieu-Bonneau, LeBlanc, & Savard, 2005). The Cronbach’s alpha in this study was .53.
Pittsburgh Sleep Quality Index (PSQI; Buysse, Reynolds, Monk, Berman, & Kupfer,
1989). The PSQI consists of 19 items and measures seven component scores (subjective sleep
quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of
sleeping medication, and daytime dysfunction) and a global score. Questions are scored on a 0
to 3 scale over a period of one-month. Evidence supports its sensitivity and specificity in
detecting good and poor sleep quality (Garland et al., 2011). In a previous study, the
Cronbach’s alpha was .80 (Garland et al., 2011). In this study the Cronbach’s alpha was .44.
Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS-16; Morin, Vallières, &
Ivers, 2007). The DBAS-16 is an abbreviated measure designed to assess the disrupted
cognition often seen in persons with sleep disturbance. Patients were asked to indicate the
extent to which they agree with the statement on a Likert scale ranging from 0 (strongly
disagree) to 10 (strongly agree). Scores of 4 or greater suggest unrealistic expectations for
sleep or that dysfunctional thoughts about sleep have become a factor in the sleep problem.
The DBAS-16 has been shown to have adequate internal consistency (Cronbach’s alpha = .77),
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and has been validated for use in different insomnia subgroups (Edinger & Carney, 2015). The
Cronbach’s alpha in this study was .79.
Sleep Diary (CSD; Carney et al., 2012). Sleep diaries are considered a reliable and
valid measure of insomnia symptoms. The CSD was used in this study at pre-treatment and
throughout the course of TeleCBT-I. The sleep diary provides night-by-night account of sleep
pattern and quality of sleep. The sleep diary was used to calculate a subjective report of sleep
efficiency throughout the course of TeleCBT-I.

Psychological Variables
Fatigue Symptom Inventory (FSI; Hann, Denniston, & Baker, 2000). The FSI is a 14item self-report measure designed to assess physical and psychological aspects of fatigue,
including perceived severity, frequency, and daily pattern of fatigue as well as its perceived
interference with quality of life. Severity is measured on a separate 11-point scale (0 = not at
all fatigued; 10 = as fatigued as I could be) that assess most, least, and average fatigue in the
past week, as well as, current fatigue. The FSI has been validated with males and females with
cancer diagnosis. Previous research determined that a mean score of 3 or greater indicate
clinically meaningful fatigue. The Cronbach’s alpha in a previous study was .95 (Stein,
Jacobsen, Blanchard, & Thors, 2004). In this study the Cronbach’s alpha was .92.
Functional Assessment of Cancer Therapy-General, Version 4 (FACT-G; Cella et al.,
1993). The FACT-G is a 27-item instrument that measures four primary quality of life
domains: Physical well-being (PWB), Social/Family well-being (SWB), Emotional wellbeing
(EBW), and Functional well-being (FWB) The statements use a 5-point rating scale (0 = Not at
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all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much). Sample items include:
“I feel sad” and “I have accepted my illness.” FACT-G total score is computed as the sum of
the four subscale scores with a possible range of 0-108 points. Higher scores are indicative of
less dysfunction. In this study, missing values were not manipulated as the answer response for
each patient was over 80% (more than 22 of 28 items). Normative data of adult cancer patients
(N = 2,236) was used to determine better functional well-being for each subscale and
composite score as follows: PWB (Normal, M = 16-27; Dysfunctional, M ≤ 15, Better
Functioning, M ≥ 28), SWB (Normal, M = 17-22; Dysfunctional, M ≤ 16, Better functioning,
M ≥ 23), EWB (Normal, M = 15-18; Dysfunctional, M ≤ 14, Better functioning, M ≥ 19), FWB
(Normal, M = 13-19; Dysfunctional, M ≤ 12, Better functioning, M ≥ 20), and FACT General
(Normal, M = 65-81; Dysfunctional, M ≤ 64, Better functioning, M ≥ 82) (Cella, 2007). The
instrument developers reported a Cronbach alpha of .89. In this study the Cronbach’s alpha
was .44.
Quality of Life for Cancer Survivor Version (QOL-CSV; Ferrell, Hassey Dow, &
Grant, 1995). The QOL-CSV was designed to measure the specific concerns of long-term
cancer patients. The QOL-CSV is based on previous versions of the QOL instrument
developed by researchers at the City of Hope National Medical Centre (Grant, Padilla, and
Ferrell). The QOL-CSV consists of 41 items representing the four domains of quality of life
incorporating physical, psychological, social, and spiritual well-being. Each item is rated on an
anchored scale from 0 to 10. The higher the scores the better quality of life the individual
endorses (Ferrell, Hassey Dow & Grant, 1995). In a previous study, the Cronbach’s alpha was
.93 (B. Ferrell, Hanson, & Grant, 2013). The Cronbach’s alpha in this study was .80.
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Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983). The HADS
consists of seven-item anxiety and depression subscales. Scores ranged from 0-3 with 21 as the
maximum score for each subscale. Higher scores reflect higher anxiety or depressive
symptoms. Scores between 0-7 = Normal, 8-10 = Borderline abnormal (borderline case) and
11-21 = Abnormal (case). Zigmond and Snaith (1983) reported a Cronbach alpha of .85 for the
anxiety and .83 for the depression subscale, respectively. In this study the Cronbach’s alpha
were .86 for the overall scale, .76 for the anxiety subscale and .85 for the depression subscale.

Feasibility
Treatment Satisfaction Questionnaire (TSQ). The TSQ was developed for this study to
assess patients' overall experience and satisfaction with the TeleCBT-I program (see Appendix
I). The TSQ was administered at post-treatment only and consisted of closed- and open-ended
questions. Patients were asked to rate nine statements evaluating specific aspects of the
treatment experience. Statements were rated using a 3-point scale from 0 (Strongly Disagree)
to 3 (Strongly Agree). Sample items include: “The program has motivated me to work on my
sleep problems” and “I gained greater understanding of my sleep problem(s).” Items were
averaged and summed to provide a total score. Negative scored items were reversed and higher
scores were indicative of positive experience. Four statements examined clinicians’
performance as perceived by patients using a 3-point scale from 0 (Strongly Disagree) to 3
(Strongly Agree). Sample items include: “The practitioner understood my sleep problems and
concerns” and “The practitioner was good at her/his job.” Items were averaged and summed to
compute a composite score of clinician’s performance.
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Additionally, the TSQ measured treatment adherence based on the number of
completed sessions and by asking patients how often they completed homework and practiced
the treatment recommendations at post-treatment. Specifically, patients were asked “Overall,
how often did you practice the suggested homework or daily practice?” with five possible
answers (daily, almost daily [4-6 days/week], occasionally [1-3 days/week], rarely [0-1
days/week], never ([0 day/week]). Further, overall satisfaction with the TeleCBT-I program
and helpfulness of program manual were each evaluated with one item using a 4-point scale
from 0 (Very Dissatisfied or helpful) to 3 (Very Satisfied or Helpful). Moreover, patients were
asked whether they would recommend the TeleCBT-I program to other patients using a 4-point
scale from 0 (Not at all likely) to 4 (Extremely likely).
Qualitative questions to ascertain what aspects of the program patients liked or disliked
included: “What did you find most helpful about the Sleeping Well Program?” and “What did
you find least helpful about the Sleeping Well Program?” Responses were reviewed to identify
major themes. Lastly, the TSQ included questions to determine major changes in patients’
health, treatment and life circumstances that could affect treatment outcomes.

Demographics
Baseline demographic and medical characteristics included demographic (age, marital
status, employment) and medical information (history of sleep problems, months since
diagnosis, cancer type, cancer location, cancer stage, and treatment).
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Post-treatment
All patients were asked to complete the post-treatment measures. The post-treatment
measures were similar as the pre-treatment measures with the exception of the TSQ, which was
developed for this study. Only those in the TeleCBT-I group were asked to complete the TSQ.
The TeleCBT-I group completed the post-treatment measures during the last portion of their
fourth treatment session, while the control group completed the post-treatment measures four
weeks after the clinical interview. Patients were given the option to complete the measures in
person or by phone. Following, patients were mailed a letter thanking them for their
participation in the study. In addition, the letter included general sleep recommendations and
patient’s individualized scores on insomnia severity, sleep quality, depression and anxiety at
pre- and post-treatment. Appendix J shows the template for the end treatment letter.

One-Month Follow-Up
Given that RCTs often estimate treatment effects by evaluating follow-up outcomes
between treatment groups (Karlsson & Bergmark, 2015), both treatment groups were asked to
complete follow-up measures. Patients in the TeleCBT-I group completed follow-up measures
four weeks after completing treatment, while the control group completed follow-up measures
four weeks after post-measures. Patients in the control group were offered the TeleCBT-I
treatment after completing follow-up measures.
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Statistical Analyses

Data Preparation
All analyses were performed using SPSS version 25 (IBM). Data was entered and
verified independently by two research assistants. Examination of missing data, outliers and
distributions was performed using standard procedures as outlined by Tabachnick & Fidell
(2013). After inspecting data for accuracy, missing values were evaluated. Missing values
detected were minimal and accounted for less than 5% on each of the few variables that had
missing values. As a result, no missing data was imputed and missing cases were excluded
using listwise deletion.
Normality was assessed by evaluating plots, and computing skewness and kurtosis.
Considering the small sample size of this study (N < 50), skewness and kurtosis were evaluated
using conventional and conservative standards as recommended by (Tabachnick & Fidell,
2007; Tabachnick & Fidell, 2013). Except for physical well-being, all variables had skewness
and kurtosis scores below the absolute value of 3.29. Outliers were identified by evaluating
studentized residuals at a multivariable level, including the two treatment groups and three
time points together. Studentized residual values greater than the absolute value of 3.00 were
considered outliers. Using this parameter, one case was identified as an outlier on HADS
anxiety and QOL physical subscales at one-month follow-up.
Based on the pattern of relatively normal distribution across variables, parametric
statistics were computed. Outliers were removed from analyses as appropriate and results with
and without outliers were reported. The assumption of sphericity was evaluated using
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Mauchly’s test to determine whether the variances of differences were roughly equal. The
Greenhouse-Geisser estimate was used when the sphericity assumption was not met as per
recommended statistical parameters (Field, 2013; Tabachnick & Fidell, 2013).

Data Analyses
The TeleCBT-I and control groups were compared using t-tests, chi-square or Fisher’s
exact test analyses, as appropriate, on demographic, clinical variables and outcome variables at
pre-treatment. Repeated measures analysis of variance (RM ANOVA) was used to evaluate the
difference in the rates of change between the TeleCBT-I and control groups over the three time
points. The basic model of group (coded as TeleCBT-I =1 and Control = 0), Time (pretreatment, post-treatment, follow-up), and group x time as fixed effects. The outcome models
included a treatment main effect to determine whether there is an overall difference between
groups and a time main effect to determine whether scores changed over time. The main
interest was in the group x time interaction effects to address the hypotheses that change by
time differed by treatment group. Measures that demonstrated a significant treatment x time
interaction were included in follow-up analyses.
Follow-up analyses followed the general linear model with three time points.
Bonferroni adjusted post hoc tests were conducted to examine treatment differences in changes
from pre-treatment to post-treatment and changes from pre-treatment to follow-up.
Additionally, to demonstrate clinically meaningful changes at different time points, the
insomnia severity scores were coded using its clinical cut off as: No clinically significant
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insomnia (0-7), Subthreshold insomnia (8-14), Clinical insomnia (moderate severity) (15-21),
and Clinical insomnia (severe) (22-28).

Effect Size
Partial eta2 is commonly used in ANOVA designs as a measure of effect size and is
often recommended particularly for repeated measures analyses (Field, 2013). In this study,
partial eta2 was used to estimate the percentage of variance in each of the effects (main effects
and interactions). Results are interpreted as percentages of variance by moving the decimal
point two places to the right. In addition, partial eta2 is interpreted using cut offs for the
magnitude of the effect as follows: .01 (small), .06 (medium) and .14 (large) (Cohen, 1988).
Hedges’ g was computed as an additional measure to estimate the magnitude of effect size by
treatment groups. Hedges’ g was chosen instead of Cohen’s d because it accounts for small and
unequal sample sizes (Hand, 2012). Hedges’ g is interpreted using the Cohen’s criteria for
small (0.2), medium (0.5) and large (0.8) treatment effects.

Sample Size and Power Analyses
Repeated measures designs offer several benefits over independent measures designs
(Field, 2013). Broadly, by including the same participants within each condition of the
independent variables, the variance and bias caused individual differences is reduced. The
results of the error term tend to be smaller producing greater statistical power. That is, if an
effect exists, it is more likely to be detected. Lastly, repeated measures designs require a
smaller number of participants (Field, 2013). Considering the merits of repeated measures
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designed mentioned above, sensitivity analyses were computed to determine the population
effect size for the study sample (Cohen, 1988).
Power analyses were computed with G Power 3.1.9.2. With an alpha level of .05,
statistical power of .80, and a total sample size of 35, effect sizes > d = 0.86 could be detected
when evaluating whether there is a mean difference between the TeleCBT-I and the control
group (Cohen, 1988). Sensitivity analyses were also computed for the evaluation of mean
differences between groups for time and group x time interactions using standard parameters
(alpha = .05, power = .80) and sample size of 35 for three measures and two groups. With these
statistical parameters, an effect size > d = 0.40 could be detected (Cohen, 1988).
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Intention to Treat Analysis
The intention to treat (ITT) analysis is typically recommended for randomized
controlled trials (Fisher et al., 2017; Ten Have et al., 2009) as it reflects real-world clinical
practices where patients discontinue treatment or do not engage in treatment at all. ITT
estimates treatment effects based on all randomized participants regardless of whether they
adhered or completed the assigned treatment (Fisher et al., 2017; Hernán & Hernández-Díaz,
2012). The application of ITT analysis is critical for studies with substantial missing data
resulting from lack of adherence and drop outs (Hernán & Hernández-Díaz, 2012). However,
ITT also has its disadvantages as it may dilute the effects of a treatment due to noncompliance,
and add heterogeneity in the sample by mixing together participants who are noncompliant,
compliant, and drop outs. Further, it does not assess treatment efficacy accurately as it
considers participants who have not received the intervention or have not completed the entire
dose of an intervention or treatment (Gupta, 2011).
One alternative to ITT analysis is the as per-protocol (PP) analysis. PP analysis
includes a subset of the ITT population by including participants who completed treatment
without major protocol deviations and excluding those who did not complete treatment or did
not receive the treatment (Gupta, 2011; Hernán & Hernández-Díaz, 2012). In fact, researchers
have argued that it is advisable to exclude participants post-randomization if they did not
receive the treatment and their allocation does not impact the chances of other participants to
receive the treatment (Fergusson, Aaron, Guyatt, & Hébert, 2002). Thus, while ITT tends to
make two treatments look similar, one advantage of PP is that it does a better job at reflecting
treatment differences by analyzing data from participants who completed treatment and
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provided outcome measures. Although PP estimates the true efficacy of a treatment, it may
provide exaggerated treatment effects. Given the above mentioned strengths and limitations of
these statistical analyses, the CONSORT guidelines for parallel group RCTs recommend that
both ITT and PP analyses should be reported to allow participants to better interpret treatment
effects (Moher et al., 2010)
Considering the entire randomized population for this study (N = 39), 35 patients
completed pre-and post-treatment measures, 3 did not receive the TeleCBT-I treatment and
only one 1 patient dropped out without completing the treatment, PP analysis was deemed
more appropriate as the main goal of the study is to evaluate treatment efficacy. ITT analysis
was also performed to adhere to the CONSORT guidelines and ascertain the potential for
selection bias (Moher et al., 2010). ITT analysis was conducted using the last observation
carried forward (LOCF) for the four patients who did not complete the intervention and posttreatment measures. Results from ITT analysis are presented after the main PP results.
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CHAPTER FOUR: RESULTS
Demographic and Sample Characteristics
Patients were recruited in the study from January 2018 through March 2019. The total
sample comprised 35 cancer patients who completed pre-treatment and post-treatment
measures. Most patients were females (n = 30, 85.71%) with a mean age of 55.26 years (SD =
10.72; range 29-74). Over half of the sample self-identified as non-Hispanic Whites (n = 20,
57.1%), while a quarter as Hispanics (n = 9, 25.7%), and a small portion as Blacks/African
Americans (n = 4, 11.4%) and mixed race/ethnicity (n = 2, 5.7%). Marital status was fairly
distributed as patients reported being currently married (n = 13, 37.1%), divorced (n = 10,
28.6%), single (n = 8, 22.9%) or widowed (n = 4, 11.4%). Most patients were either full-time
employed (n = 13, 37.1%) or retired (n = 12, 34.3%). Almost the entire sample had completed
some college, higher education or more (n = 33, 94.3%). Patients’ reported personal annual
income ranged from less than $25,000 (n = 12, 34.2%) to $50,000 or more (n = 14, 40%).
Table 3 depicts the demographic and sample characteristics by treatment group. There
were no statistically significant differences between treatment groups on demographic and
sample characteristics variables, except for personal income.
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Table 3.
Demographic and sample characteristics by treatment group

Variables
Age (years)
Sex
Female
Race/Ethnicity
Non-Hispanic White
African American
Hispanic
Mixed
Marital status
Single
Married
Divorced
Widowed
Highest Level of Education
High School or GED
Some College
Bachelor’s degree
Master’s degree
Employment
Part-time
Full-time
Unemployed
Retired
Disabled
Income
Less than $15,000
15,000-24,999
25,000-34,999
35,000-49,999
50,000-74,999
75,000 or more
Missing

TeleCBT-I
(n = 19)
Mean
SD
No
%
56.37
9.64
Range = 36 to 71

Control
(n = 16)
Mean
SD
No
%
53.94
12.07
Range = 29 to 74

p
.512
.642

17

89.5

13

81.3

12
2
3
2

63.2
10.5
15.8
10.5

8
2
6
-

50
12.5
37.5
-

.377

.440
3
6
7
3

15.8
31.6
36.8
15.8

5
7
3
1

31.3
43.8
18.8
6.3

5
7
7

26.3
36.8
36.8

2
5
7
2

12.5
31.3
43.8
12.5

2
8
2
7
-

10.5
42.1
10.6
36.8
-

2
5
1
5
3

12.5
31.3
6.3
31.3
18.8

2
3
4
4
6
-

10.5
15.8
21.1
21.1
31.6
-

4
3
4
1
3
1

25
18.8
25
6.3
18.8
6.3

.239

.490

.048*

Note. Significance tests for continuous variables were determined with independent samples t-tests (2tailed), while Fisher’s exact tests were used for dichotomous and categorical variables.
Abbreviations: TeleCBT-I, Telephone-delivered cognitive behavioral therapy for insomnia; SD, standard
deviation; No, frequency; %, percentage; GED, general educational development test.
Income (n = 34).
*p < .05.
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Similarly, there was no difference between treatment groups on cancer related
variables. In the total sample, patients reported having a cancer diagnosis of stage I (n = 12,
34.3%), stage II (n = 7, 20%), state III (n = 5, 14.3%), stage IV (n = 5, 14.3%), and some did
not know their cancer stage diagnosis (n = 6, 17.13%). Most patients reported a breast cancer
diagnosis (n = 20, 57.1%) and were diagnosed either two or more years ago (n = 17, 48.6%) or
less than a year ago (n = 12, 34.3%).
In terms of past and current cancer treatment, most patients reported that they received
surgery (n = 27, 77.1%), chemotherapy (n = 24, 68.6%), radiotherapy (n = 24, 68.6%), and
hormonal therapy (n = 15, 42.9%). However, while a significant portion of patients were not
undergoing cancer treatment at the time of the study (n = 16, 45.7%), more than half were
receiving hormonal therapy (n = 9, 25.7%), chemotherapy (n = 4, 11.4%), radiotherapy (n = 4,
11.4%), and/or surgery (n = 4, 11.4%). Table 4 shows the cancer related information by
treatment group.
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Table 4
Cancer Related Information by Treatment Group

Variables
Cancer stage
Stage I
Stage II
Stage III
Stage IV
Don’t know
Time since cancer diagnosis
Less than one year
One to two years ago
Two or more years ago
Cancer location
Breast
Brain
Skin
Colon
Head and Neck
Kidney
Musculoskeletal
Lung
Blood
Ovarian
Past cancer treatments
Chemotherapy
Radiation therapy
Surgery
Hormone therapy
No past treatment
Current cancer treatments
Chemotherapy
Radiation Therapy
Surgery
Hormone therapy
No current treatment

TeleCBT-I
(n = 19)
No
%

Control
(n = 16)
No
%

p
.369

7
6
3
3
1

36.8
26.3
15.8
15.8
5.3

5
2
2
2
5

31.3
12.5
12.5
12.5
31.3

6
5
8

31.6
26.3
42.1

6
1
9

37.5
6.3
56.3

13
1
1
1
1
1
1

68.4
5.3
5.3
5.3
5.3
5.3
5.3

7
3
1
1
2
1
1
-

43.8
18.8
6.3
6.3
12.5
6.3
6.3
-

15
13
14
10
-

78.9
68.4
73.7
52.6
-

9
11
13
5
1

56.3
68.8
81.3
31.3
6.3

.273
>.05
.700
.306
.457

3
2
2
7
6

15.8
10.5
10.5
36.8
31.6

1
2
2
2
10

6.3
12.5
12.5
12.5
62.5

.608
>.05
>.05
.135
.095

.319

.406

Note. Differences by group were determined with Chi-square and Fisher’s exact tests.
Abbreviations: TeleCBT-I, Telephone-delivered cognitive behavioral therapy for insomnia; SD, standard
deviation; No = Frequency; % = Percentage.
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Pre-treatment Characteristics

Sleep Variables
At pre-treatment, the average insomnia severity score as measured by the ISI was 17.66
(SD = 4.07) indicating clinically significant insomnia with moderate severity for the entire
sample. The average sleep quality as measured by the PSQI was 11.83 (SD = 3.44) and
indicated poor sleep quality. Patients reported dysfunctional beliefs about sleep as measured by
the DBAS-16 with a mean score of 5.24 (SD = 1.62). Further, about half of the patients were
taking prescribed sleep medications prior to treatment (n = 18, 51.4%). There was no
difference between groups on any of the sleep outcome variables at pre-treatment. Table 5
depicts the sleep outcome measures at pre-treatment for each treatment group.

Table 5.
Scores on Sleep Measures and Group Differences at Pre-treatment

Variables

TeleCBT-I
(n = 19)
Mean
SD

Control
(n = 16)
Mean
SD

ISI
PSQI
DBAS-16
Sleep Medication % (n)

17.79
11.95
4.98
52.6

17.50
11.69
5.55
8

3.57
3.05
1.50
10

4.71
3.96
1.75
50

t (33) / 2

p

95% CI

.207
.219
-1.02
.024

.837
.828
.315
> .05

[-2.56, 3.14]
[-2.15, 2.67]
[-1.68, 0.56]

Note. Significance tests were determined with independent samples t-tests (2-tailed) or chi-square tests.
Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; SD, standard
deviation; ISI, insomnia severity inventory; PSQI, Pittsburgh sleep quality index; DBAS-16, dysfunctional
beliefs about sleep.
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Psychological Variables
In the entire sample, patients reported scores higher than three, indicating clinically
significant levels of fatigue at pre-treatment (M = 4.74, SD = 2.01) as measured by the FSI.
However, patients reported no clinical levels of anxiety (M = 8.14, SD = 4.35) and depression
(M = 6.17, SD = 4.23) as measured by the HADS.
In terms of functional assessment of health-related quality of life, the FACT-G pretreatment scores were examined using the normative data for cancer patients (Brucker, Yost,
Cashy, Webster, & Cella, 2005). In the total sample, patients reported normal levels of general
functioning (M =72.03, SD = 17.43), physical well-being (M = 19.37, SD = 4.96), social/family
well-being (M = 19, SD = 6.27), emotional well-being (M = 17.06, SD = 4.63), and functional
well-being (M = 16.6, SD = 5.31).
In terms of quality of life, patients reported scores slightly greater than the midpoint on
the quality of life measure (QOL-CS) suggesting positive, but not optimal levels of overall
quality of life (M = 5.72, SD = 1.45), physical QOL (M = 6.26, SD = 1.70), psychological QOL
(M = 5.84, SD = 1.96), social QOL (M = 5.82, SD = 2.11), and spiritual QOL (M = 6.05, SD =
2.15). Table 6 presents the results for the psychological outcome variables by treatment group.
No differences were found between groups in all psychological variables.

45

Table 6.
Scores on Psychological Measures and Group Differences at Pre-treatment

Variables

TeleCBT-I
(n = 19)
Mean
SD

Control
(n = 16)
Mean
SD

t (33)

p

95% CI

FSI
HADS-Depression
HADS-Anxiety
FACT-General
Physical well-being
Social/Family well-being
Emotional well-being
Functional well-being
QOL-CSV Total
Physical
Psychological
Social
Spiritual

4.60
5.58
7.89
71.37
19.79
18.42
17.11
16
5.83
6.23
5.86
6.09
5.96

4.90
6.88
8.44
72.81
18.88
19.69
17
17.31
5.59
6.3
5.82
5.49
6.16

-.422
-.902
-.363
-.241
.538
-.590
.066
-.723
.469
-.115
.059
.826
-.272

.676
.374
.719
.811
.594
.559
.948
.475
.642
.909
.953
.415
.787

[-1.69, 1.11]
[-4.22, 1.63]
[-3.58, 2.50]
[-13.64, 10.76]
[-2.55, 4.37]
[-5.64, 3.10]
[-3.14, 3.35]
[-5.00, 2.38]
[-.78, 1.25]
[-1.26, 1.12]
[-1.34, 1.42]
[-.87, 2.05]
[-1.70, 1.30]

1.62
4.80
4.22
19.21
5.13
6.68
4.99
5.88
1.50
1.64
2.25
1.82
2.30

2.44
3.44
4.62
15.63
4.87
5.88
4.32
4.63
1.42
1.81
1.63
2.43
2.02

Note. Significance tests were determined with independent samples t-tests (2-tailed).
Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; FSI, fatigue
symptom inventory; HADS-Depression, depression subscale of hospital anxiety and depression scale; HADSAnxiety, anxiety subscale of hospital anxiety and depression scale; FACT, functional assessment of cancer
therapy; QOL-CSV, quality of life patient/cancer survivor version.
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Post-treatment Outcomes

Sleep Variables

Insomnia Severity
The TeleCBT-I intervention resulted in significantly greater improvements in insomnia
severity than the control group. The ISI mean decreased from 17.79 (SD = 3.57) to 7.58 (SD =
3.78) in the TeleCBT-I group reaching no clinically significant level at post-treatment.
However, the ISI mean decreased from 17.50 (SD = 4.71) to 14.88 (SD = 5.82) in the control
group sustaining clinically significant levels of insomnia severity at post-treatment. Hedges’ g
of the TeleCBT-I group was 2.72, while the Hedges’ g of the control group was 0.48. There
was significant within-subjects main effect across pre- and post-treatments, F(1, 33) = 81.01, p
< .001, partial 2 = .711, and a significant main effect between treatment groups, F(1, 33) =
6.8, p = .014, partial 2 = .171. The significant Group x Time interaction, F(1, 33) = 28.29, p <
.001, partial 2 = .462, revealed that both groups reported decreased symptoms of insomnia
severity at post-treatment. Post hoc comparisons revealed statistically significant differences
between pre-treatment and post-treatment in both treatment groups, TeleCBT-I (p < .001) and
control (p = .018). Figure 1 shows the mean scores on insomnia severity for the TeleCBT-I and
control groups from pre-treatment to post-treatment.
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20

g = 0.48

18

*

ISI Mean Scores

16
14
12
10

g = 2.72

***

Pre

8

Post

6
4
2
0

TeleCBT-I

Control
Time

Figure 1.
Scores on Insomnia Severity by Group at Pre-treatment and Post-treatment
Note. Error bars represent 95% confidence intervals.
*p < .05, ***p < .001.

To examine meaningful clinical change in insomnia severity scores as a function of ISI
clinical cut offs (0-7 = No clinically significant insomnia; 8-14 = Subthreshold insomnia, 15-21
= clinical insomnia/moderate severity, 22-28 = clinical insomnia/severe) from pre- to posttreatment, Fisher’s exact tests were computed and demonstrated no difference between
TeleCBT-I and control groups at pre-treatment. However, a statistical significance was
observed between treatment groups at post-treatment where those in the TeleCBT-I group were
more likely to endorse no clinically significant insomnia compared to control group (n = 12,
63.2% vs. n = 1, 6.3%), respectively (p = .001).
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Sleep Quality
As shown in Figure 2, the TeleCBT-I group reported significantly greater
improvements in sleep quality at post-treatment compared to the control group. The TeleCBT-I
group showed a significant reduction from pre-treatment (M = 11.95, SD = 3.05) to posttreatment (M = 6, SD = 2.36), while the control group showed virtually no change from pretreatment (M = 11.69, SD = 3.96) to post-treatment (M = 11.06, SD = 4.06) in sleep quality.
Hedges’ g of the TeleCBT-I group was 2.14, while the Hedges’ g of the control group was
0.15. There was significant within-subjects main effect across pre- and post-treatments, F(1,
33) = 37.67, p < .001, partial 2 = .533, and a significant main effect between treatment
groups, F(1, 33) = 5.65, p = .023, partial 2 = .146. There was also a significant Group x Time
interaction, F(1, 33) = 24.7, p < .001, partial 2 = .428. Post hoc comparisons revealed a
statistically significant difference between pre-treatment and post-treatment in the TeleCBT-I
group only (p < .001).
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Figure 2.
Scores on Sleep Quality by Group at Pre-treatment and Post-treatment
Note. Error bars represent 95% confidence intervals.
***p < .001.

Dysfunctional Beliefs about Sleep
The TeleCBT-I group showed reduced dysfunctional sleep beliefs from pre-treatment
(M = 4.98, SD = 1.50) to post-treatment (M = 3.28, SD = 1.65), while the control group showed
slightly similar levels of dysfunctional sleep beliefs from pre-treatment (M = 5.55, SD = 1.75)
to post-treatment (M = 5.01, SD = 1.99). Hedges’ g of the TeleCBT-I group was 1.06, while
the Hedges’ g of the control group was 0.28. There was a significant within-subjects main
effect across pre- and post-treatments, F(1, 33) = 22.32, p < .001, partial 2 = .403, and a
significant main effect between treatment groups, F(1, 33) = 4.63, p = .039, partial 2 = .123.
There was also a significant interaction between treatment group and time, F(1, 33) = 6.08, p =
50

.019, partial 2 = .156. Post hoc comparisons revealed a statistically significant difference
between pre-treatment and post-treatment in the TeleCBT-I group only (p < .001). Figure 3
exhibits the mean scores on dysfunctional beliefs about sleep by treatment groups from pretreatment to post-treatment.
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g = 0.28
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TeleCBT-I
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Pre

Post

Figure 3.
Scores on Dysfunctional Beliefs about Sleep by Group at Pre-treatment and Posttreatment
Note. Error bars represent 95% confidence intervals.
***p < 0.001.

Sleep Medication
Patients in the TeleCBT-I group reported reduced use of sleep medication from pretreatment (52.63%, n = 10) to post-treatment (15.79%, n = 3).
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Table 7.
Scores on Sleep Measures by Group at Pre-treatment and Post-treatment and Treatment Effects

Pre-treatment

Post-treatment

LMM Statistical Tests (Type III tests of fixed effects)
Time Effect
Group Effect
Group x Time Interaction
Partial
Partial
Partial
F(1, 33)
p
F(1, 33)
p
F(1, 33)
p
2
2
2

Variables
Mean
SD
Mean
SD
g
ISI
TeleCBT-I
17.79
3.57
7.58a***
3.78
2.72
81.01
< .001
.711
6.80
.014
.171
28.29
< .001 .462
Control
17.50
4.71
14.88a*
5.82
0.48
PSQI
TeleCBT-I
11.95
3.05
6 a***
2.36
2.14
37.67
< .001
.533
5.65
.023
.146
24.70
< .001
.428
Control
11.69
3.96
11.06
4.06
0.15
DBAS-16
TeleCBT-I
4.98
1.50
3.28 a***
1.65
1.06
22.32
< .001
.403
4.63
.039
.123
6.08
.019
.156
Control
5.55
1.75
5.01
1.99
0.28
Note. TeleCBT-I (n = 19); Control (n = 16); Group effect sizes were computed as Hedges’ g values.
Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; ISI, insomnia severity inventory; PSQI, Pittsburgh sleep
quality index; DBAS-16, dysfunctional beliefs about sleep.
Means with subscript (a) are significantly different according to post hoc comparisons.
*p < .05, **p < .01, ***p < .001.
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Psychological Variables

Fatigue
As presented in Table 8, the TeleCBT-I group mean was reduced from pre-treatment (M
= 4.60, SD = 1.62) to post-treatment (M = 3.01, SD = 2.48), reaching no clinically significant
level of fatigue at post-treatment. However, the control group showed slightly increased levels of
fatigue from pre-treatment (M = 4.89, SD = 2.44) to post-treatment (M = 5.27, SD = 2.09).
Hedges’ g of the TeleCBT-I group was 0.74, while the Hedges’ g of the control group was 0.16.
The results revealed only statistically significant Group x Time interaction on fatigue, F(1, 33) =
10.21, p < .003, partial 2 = .236. Post hoc comparisons yielded a statistically significant
difference between pre-treatment and post-treatment in the TeleCBT-I group only (p = .002).

Depression
The TeleCBT-I group reported similar scores from pre-treatment (M = 5.58, SD = 4.80)
to post-treatment (M = 5.37, SD = 5.93) on depression. However, the control group reported
slightly increased symptoms of depression from pre-treatment (M = 6.88, SD = 3.44) to posttreatment (M = 7.13, SD = 4.23). Hedges’ g of the TeleCBT-I group was 0.04, while the Hedges’
g of the control group was -0.06. The effects of Time (p = .975), Group (p = .314), and Time x
Group interaction (p = .711) were not significant on depression.
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Anxiety
Both treatment groups reported slightly reduced scores from pre-treatment to posttreatment on anxiety. The HADS-Anxiety score decreased from 7.89 (SD = 4.22) to 6.53 (SD =
3.22) in the TeleCBT-I group and from 8.44 (SD = 4.61) to 7 (SD = 4.27) in the control group.
Hedges’ g of the TeleCBT-I group was 0.36, while the Hedges’ g of the control group was 0.32.
Although no main effects were observed by Group (p = .95) and Group x Time interaction (p =
.69), there was a statistically significant Time effect on anxiety, F(1, 33) = 5.90, p < .021, partial
2 = .152. However, post hoc comparisons were not statistically significant for both treatment
groups.

Functional Assessment of Cancer Therapy
Table 8 shows the mean and standard deviations of FACT-G and its subscales by
treatment group. The FACT general and subscales scores were within the normal range of
functioning in both treatment groups at pre-treatment and post-treatment. Nonetheless, the
TeleCBT-I group resulted in slightly increased scores, while the control group reported slightly
decreased scores from pre-treatment to post-treatment on the FACT general and all its subscales.
Hedges’ g of the TeleCBT-I group for FACT general and all its subscales ranged from 0.24 to
0.45, while for the control group ranged was from 0.04 to 0.30. Overall, no main effects were
observed in the FACT general and its subscales, except for Group x Time interaction on FACT
general, F(1, 33) = 6.4, p = .016, partial 2 = .162, physical well-being subscale, F(1, 33) = 8.20,
p = .007, partial 2 = .199 and functional well-being subscale, F(1, 33) = 5.98, p = .020, partial
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2 = .153. Post hoc comparisons resulted in statistically significant differences between pretreatment and post-treatment in the TeleCBT-I group for physical well-being (p = .017) and
functional well-being (p = .051) subscales, while the control group revealed a statistically
significant difference between pre-treatment and post-treatment only on the FACT general (p =
.020).

Quality of Life in Cancer Patients
Table 9 shows the mean and standard deviations of QOL-CSV and its subscales by
treatment group. A similar trend was found in quality of life as the TeleCBT-I group reported
slightly improved quality of life from pre-treatment to post-treatment in QOL-CSV total and all
its subscales. In contrast, the control group showed no changes on QOL-CVS total and its
psychological and social subscales. Furthermore, the control group showed slightly decreased
scores on QOL physical, but increased scores on QOL spiritual from pre-treatment to posttreatment. Hedges’ g of the TeleCBT-I group for QOL-CVS Total and all its subscales ranged
from 0.10 to 0.80, while for the control group ranged from was 0.01 to 0.36. No significant main
and interaction effects were found on QOL-CVS total and all its subscales, except for the Group
x Time interaction on QOL physical, F(1, 33) = 15.05, p < .001, partial 2 = .313. The same
pattern was observed when analyses excluded one outlier for the QOL physical subscale. That is,
the QOL physical subscale showed significant Time x Group interaction, F(1, 32) = 13.17, p =
.001, partial 2 = .292, but no main effects. Post hoc comparisons yielded a statistically
significant difference between pre-treatment and post-treatment in the TeleCBT-I group for QOL
physical subscale only (p = .001)
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Table 8.
Scores on Psychological Measures by Group at Pre-treatment and Post-treatment and Treatment Effects
Pre-treatment

Post-treatment

LMM Statistical Tests (Type III tests of fixed effects)
Time Effect
Group Effect
Group x Time Interaction
Partial
Partial
Partial
F(1, 33)
p
F(1, 33)
p
F(1,33)
p
2
2
2

Variables
Mean
SD
Mean
SD
g
FSI
TeleCBT-I
4.60
1.62
3.01 a**
2.48
0.74
3.86
.058
.105
3.61
.066
.099
10.21
.003** .236
Control
4.89
2.44
5.27
2.09
0.16
HADS-Depression
TeleCBT-I
5.58
4.80
5.37
5.94
0.04
.001
.975
.000
1.05
.314
.031
.140
.711
.004
Control
6.87
3.44
7.12
4.23 -0.06
HADS-Anxiety
TeleCBT-I
7.89
4.22
6.53
3.22
0.36
5.90
.021*
.152
.163
.689
.005
.004
.953
.000
Control
8.44
4.62
7
4.27
0.32
FACT General
TeleCBT-I
71.37 19.21
79.58
22.04 0.39
.326
.572
.010
.799
.378
.024
6.4
.016*
.162
Control
72.81 15.63 67.63 a* 17.85 0.30
Physical well-being
TeleCBT-I
19.79
5.13
22.32 a*
6.29
0.43
.000
.988
.000
3.56
.068
.097
8.20
.007**
.199
Control
18.88
4.87
16.38
7.27
0.06
Social well-being
TeleCBT-I
18.42
6.68
20.05
6.85
0.24
.045
.833
.001
.004
.951
.000
1.34
.256
.039
Control
19.69
5.88
18.56
5.93
0.19
Emotional well-being
TeleCBT-I
17.11
4.99
18.32
4.51
0.25
.732
.398
.022
.316
.578
.009
1.37
.251
.040
Control
17
4.32
16.81
4.35
0.04
Functional well-being
TeleCBT-I
16
5.88
18.89 a*
6.56
0.45
.677
.417
.020
.256
.616
.008
5.98
.020*
.153
Control
17.31
4.63
15.88
4.91
0.29
Note. Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; FSI, fatigue symptom inventory; HADS-Depression,
depression subscale of hospital anxiety and depression scale; HADS-Anxiety, anxiety subscale of hospital anxiety and depression scale; FACT, functional
assessment of cancer therapy.
Means with subscript (a) are significantly different according to post hoc comparisons; *p < .05, **p < .01.
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Table 9.
Scores on Quality of Life by Group at Pre-treatment and Post-treatment and Treatment Effects
Pre-treatment

Post-treatment

LMM Statistical Tests (Type III tests of fixed effects)
Time Effect
Group Effect
Group x Time Interaction
Partial
Partial
Partial
F(1, 33)
p
F(1, 33)
p
F(1, 33)
p
2
2
2

Variables
Mean
SD
Mean
SD
g
QOL-CSV
Total
TeleCBT-I
5.83
1.50
6.13
1.74
0.18
.232
.633
.007
.946
.338
.028
1.98
.169
Control
5.59
1.42
5.44
1.12
0.11
Physical
TeleCBT-I
6.23
1.64
7.47 a**
1.38
0.80
1.86
.182
.053
2.66
.112
.075
15.05
< .001***
Control
6.30
1.81
5.70
1.95
0.31
Psychological
TeleCBT-I
5.86
2.25
6.44
2.11
0.26
1.47
.234
.043
.316
.578
.009
1.54
.224
Control
5.82
1.63
5.81
1.33
0.01
Social
TeleCBT-I
6.09
1.82
6.37
2.15
0.14
.241
.627
.007
1.23
.276
.036
.341
.563
Control
5.49
2.43
5.47
2.14
0.01
Spiritual
TeleCBT-I
5.96
2.30
6.20
2.46
0.10
3.38
.075
.093
.372
.546
.011
.761
.389
Control
6.16
2.02
6.84
1.65
0.36
Note. Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia, QOL-CSV, quality of life-cancer survivor version.
Means with subscript (a) are significantly different according to post hoc comparisons.
Hedges’ g effect sizes were computed between pre-treatment and post-treatment scores by treatment group.
*p < .05, ***p < .001.
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.057

.313

.045

.010

.023

Follow-Up Outcomes

Sleep Variables
Patients in the TeleCBT-I group indicated that the improvements observed from pre- to
post-treatment in all sleep variables were sustained at one-month follow. Table 10 presents the
observed means for all three time points and treatment effects by treatment groups. Only the
measures that demonstrated statistically significant Group (TeleCBT-I and Control) x Time (Pretreatment and Post-treatment) interactions were included in the follow-up analyses to assess
differences between pre-treatment and follow-up and between post-treatment and follow-up.

Insomnia Severity
As shown in Figure 4, insomnia severity followed the same pattern as from pre-treatment
to post-treatment. There was significant within-subjects main effect across the three time points,
F(2, 58) = 73.20, p < .001, partial 2 = .716, and a significant main effect between treatment
groups, F(1, 29) = 12.42, p = <.001, partial 2 = .300. There was also a significant interaction
between treatment group and time, F(2, 58) = 23.04, p < .001, partial 2 = .443, with post hoc
tests revealing that there was a statistical significant difference in TeleCBT-I between pretreatment and follow-up (p < .001), but not between post-treatment and follow-up (p = .467).
However, there was a statistically difference in the control group between pre-treatment and
follow-up (p = .006) and post-treatment and follow-up (p = .043).
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Figure 4.
Scores on Insomnia Severity across the Three Time Points
Note. Error bars represent 95% confidence intervals.
* = p < .05 for significant difference between groups.
† = p < .05 for significant main effect across times by treatment group.

Sleep Quality
Similarly, for sleep quality there was significant within-subjects main effect across the
three time points, F(2, 58) = 32.10, p < .001, partial 2 = .525, and a significant main effect
between treatment groups, F(1, 29) = 9.79, p = .004, partial 2 = .252. There was also a
significant interaction between treatment group and time, F(2, 58) = 18.88, p < .001, partial 2 =
.407, with post hoc tests showing that there was a statistical significant difference in TeleCBT-I
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between pre-treatment and follow-up (p < .001), but not between post-treatment and follow-up (p
> .05). However, no statistically significance difference was found in the control group between
pre-treatment and follow-up and between post-treatment and follow-up (ps > .05). Figure 5
presents the scores on sleep quality across all time points.
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Figure 5.
Scores on Sleep Quality across the Three Time Points
Note. Error bars represent 95% confidence intervals.
* = p < .05 for significant difference between groups.
† = p < .05 for significant main effect across times by treatment group.
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Dysfunctional Beliefs about Sleep
A similar pattern was observed in beliefs about sleep as in pre-treatment and posttreatment comparisons. There was significant within-subjects main effect across the three time
points, F(2, 58) = 13.77, p < .001, partial 2 = .322, and a significant main effect between
treatment groups, F(1, 29) = 4.96, p = .034, partial 2 = .146. There was also a significant
interaction between treatment group and time, F(2, 58) = 4.65, p = .013, partial 2 = .138, with
post hoc tests showing that there was a statistical significant difference in TeleCBT-I for beliefs
about sleep between pre-treatment and follow-up (p = .002), but not between post-treatment and
follow-up (p > .05). However, no statistically significance difference was found in the control
group between pre-treatment and follow-up and between post-treatment and follow-up (ps > .05).
Figure 6 presents the scores on dysfunctional beliefs about sleep across all time points.
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Figure 6.
Scores on Dysfunctional Beliefs about Sleep across the Three Time Points
Note. Error bars represent 95% confidence intervals.
* = p < .05 for significant difference between groups.
† = p < .05 for significant main effect across times by treatment group.
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Psychological Variables

Fatigue
Although no significant main effect between treatment groups (p = .109) was found,
results shown a significant within-subjects main effect across the three time points, F(2, 58) =
3.16, p = .05, partial 2 = .098 and a significant interaction between treatment group and time,
F(2, 58) = 3.89, p = .026, partial 2 = .118. Post hoc tests showed that there was a statistical
significant difference in the TeleCBT-I group for fatigue between pre-treatment and follow-up (p
= .011), but not between post-treatment and follow-up (p > .05). However, no statistically
significant difference was found in the control group between pre-treatment and follow-up and
between post-treatment and follow-up (ps > .05). Figure 7 presents the scores on fatigue across
all time points.
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Figure 7.
Scores on Fatigue across the Three Time Points
Note. Error bars represent 95% confidence intervals.
* = p < .05 for significant difference between groups.
† = p < .05 for significant main effect across times by treatment group.

FACT General Functioning and Physical Well-Being
No statistically significant effects were observed for FACT general functioning and
FACT physical well-being (ps > .05) at follow-up. However, FACT functional well-being
showed statistically significant Group x Time interaction, F(2, 58) = 3.92, p = .025, partial 2 =
.119), but no Time and Group main effects. Nonetheless, post hoc tests revealed a statistically
significant difference between pre-treatment and follow-up in the TeleCBT-I group (p = .043).
Figure 8 depicts the scores on functional well-being across all time points.
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Figure 8.
Scores on Functional Well-being across All Three Time Points
Note. Error bars represent 95% confidence intervals.
† = p < .05 for significant change from pre-treatment to post-treatment.

Quality of Life Physical
Although there was not a statistically significant within-subjects main effect across the
three time points (p = .114), there was a significant main effect between treatment groups, F(1,
29) = 4.38, p = .045, partial 2 = .131. There was also a significant Group x Time interaction,
F(2, 58) = 14.24, p < .001, partial 2 = .329, with post hoc tests showing that there was a
statistical significant difference in TeleCBT-I for physical QOL between pre-treatment and
follow-up (p < .001), but not between post-treatment and follow-up (p = .794).
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However, analyses conducted excluding one outlier revealed a slightly different pattern,
as statistically significant differences were found for Time [F(2, 56) = 3.27, p = .045, partial 2 =
.105], and Time x Group interaction [F(2, 56) = 12.30, p = .045, partial 2 = .105] effects, with
similar results on post hoc tests showing statistical significant difference in TeleCBT-I for
physical QOL between pre-treatment and follow-up (p < .043). Given the slight difference in
results with and without outlier, analyses conducted without the outlier were interpreted. Figure
9 presents the scores on physical quality of life across all time points.
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Figure 9.
Scores on Physical Quality of Life across the Three Time Points
Note. Error bars represent 95% confidence intervals.
* = p < .05 for significant difference between groups.
† = p < .05 for significant main effect across times by treatment group.
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Table 10.
Sleep and Psychological Scores by Group for All Time Points, Treatment Effects, Effect Sizes, and Post Hoc Results
p values and Hedges’ g
in differences
Pre-treatment
Post-treatment
and Follow-up
and Follow-up
p
g
p
g

Means and Standard Deviations
Pre-treatment

Post- treatment

Follow- up

F- Tests
Time x Group
Interaction

Partial
2

Variables
ISI
TeleCBT-I
17.75 (3.84)
7.37 (3.68)
6.44 (4.53)
< .001***
2.7
.467
0.22
F(2, 58) = 23.04
.443
Control
17.73 (4.77)
15.60 (5.22)
13.87 (5.64)
.006**
0.72 .043*
0.31
p < .001***
PSQI
TeleCBT-I
12 (3.31)
6.06 (2.46)
4.94 (2.72)
< .001***
2.3
.163
0.43
F(2, 58) = 19.88
.407
Control
11.67 (4.10)
11 (4.19)
10.80 (4.16)
.917
0.21 > .05
0.42
p < .001***
DBAS-16
TeleCBT-I
5.01 (1.60)
3.24 (1.78)
3.51 (1.93)
.002**
0.84
.661
0.14
F(2, 58) = 4.65
.138
Control
5.53 (1.81)
4.90 (2.01)
5.35 (1.86)
> .05
0.10
.169
0.23
p = .023*
FSI
TeleCBT-I
4.74 (1.74)
3.33 (2.56)
3.38 (2.05)
.011*
0.71 > .05
0.02
F(2, 58) = 3.89
.118
Control
4.93 (2.52)
5.15 (2.10)
4.85 (2.04)
> .05
0.03 > .05
0.14
p = .026*
FACT General
TeleCBT-I
70.31 (20.30)
77.56 (23.44)
77 (21.80)
.312
0.31 > .05
0.02
F(2, 58) = 2.52
.080
Control
72.53 (16.13)
68.27 (18.28)
73.40 (17.77)
> .05
0.05
.166
0.28
p = .103
Physical well-being
TeleCBT-I
19.31 (5.46)
21.75 (6.71)
21.56 (4.16)
> .05
0.45 > .05
0.03
F(2, 58) = 2.84
.089
Control
18.53 (4.84)
17.20 (6.70)
19.93 (5.23)
> .05
0.27
.030
0.44
p = .067
Functional well-being
TeleCBT-I
15.44 (6.13)
18.06 (6.80)
18.75 (7.09)
.043*
0.49 > .05
0.10
F(2, 58) = 3.92
.119
Control
17.07 (4.68)
15.87 (5.08)
16.07 (5.50)
> .05
0.19 > .05
0.04
p = .036*
QOL Physical
TeleCBT-I
6.25 (1.72)
7.48 (1.44)
7.73 (1.54)
< .001*** 0.88
.789
0.16
F(2, 56) = .12.30
.305
Control
6.52 (1.76)
6.21 (1.444)
5.99 (1.53)
.359
0.31
> .05
0.14
p < .001***
Note. Pre-treatment and post-treatment samples, TeleCBT-I (n = 19), Control (n = 16); Follow-up samples, TeleCBT-I (n = 16), Control (n = 15).
Hedges’ g effect sizes were computed between pre-treatment and follow-up and between post-treatment and follow-up scores by treatment groups.
Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia, ISI, insomnia severity inventory; PSQI, Pittsburgh sleep
quality index; DBAS-16, dysfunctional beliefs about sleep; FSI, fatigue symptom inventory; FACT, functional assessment of cancer therapy; QOLCSV, quality of life-cancer survivor version.
*p < .05, **p < .01, *** p < .001
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Feasibility
A total of 35 cancer patients (30 or 85.71% females) completed the study, indicating an
overall 79.55% adherence rate for the entire sample. Two patients dropped out before initiating
treatment and were considered lost to contact. Reason for discontinuation of the study is
unknown for those lost to contact as they did not return outreach phone calls. During treatment,
two patients dropped out, one due to medical complications related to cancer treatment (after
session two), and one lost to contact (after session three). No adverse events were reported as a
result of TeleCBT-I program. There were no statistically significant difference between dropouts
and completers on insomnia severity and sleep quality as measured by ISI and PSQI (ps > .05).
Out of the 21 patients who initiated TeleCBT-I treatment, 19 completed the four
TeleCBT-I sessions, resulting in 90.48% adherence rate for the TeleCBT-I group. Booster
sessions were offered and two patients completed an additional booster session within 1-2 weeks
post-treatment. One-month follow-up was assessed based on the last treatment session or booster
session. Most patients reported that telephone-delivery format was convenient (79%; M = 2.79,
SD = .42). Additionally, more than half (n = 11, 57.89%) reported that they completed
homework and treatment recommendations almost daily, while the rest (n = 8) daily.
Patients reported high satisfaction with their overall TeleCBT-I program experience at
post-treatment. Mean score for all nine items of the patient experience questionnaire was 2.73
(SD = .36). The results for each item are presented in Figure 10. Overall, patients reported high
satisfaction (M = 3.68, SD = .75) with the program. Additionally, most patients reported that they
will likely recommend the TeleCBT-I to other cancer patients (M = 3.79, SD = .42). Out of 19
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patients, 14 indicated the program manual was very helpful. Clinician’s performance was also
rated highly (M = 2.73, SD = .36).

Patient Experience
Better understanding
Learned strategies
Satisfaction with sleep
Comfort talking about sleep
Convenience of telephone delivery
Liked the program structure
Adequate time to talk
Enjoyed the sessions
Increased motivation
Patient Experience
0
Strongly Disagree

1

2

3
Strongly Agree

Figure 10.
Patient Reported Overall Experience and Satisfaction with TeleCBT-I

Qualitative questions yielded specific recommendations for the TeleCBT-I program.
Overall, patients favored educational information of healthy sleep and how sleep is related to
cancer, as well as, gaining self-awareness of sleep patterns (n = 9, 47.37%; e.g. “I learned a lot!
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It changed my way of doing things and I told all my family”, “It gave me more awareness of my
sleep problems”, “Realizing that sleep was important for cancer treatment, no other provider
mentioned that to me”), sleep hygiene (n = 7; 36.84%; “Tips on preparing to go to sleep, sleep
hygiene”) and the combination of behavioral and cognitive techniques (n = 14, 73.68%;
“Different strategies to overcome negative sleep thoughts, [and] like covering my clock, it was a
secret weapon!”).
Although, a sizeable number of patients reported no improvements needed (n = 8,
42.11%; “All positive, life saver!”, the majority provided specific recommendations to improve
TeleCBT-I. Recommendations included reducing the overall amount of information and
strategies as the program was potentially a source of additional anxiety (n =1), and improve the
relaxation log as it was confusing (n =1). Patients also identified aspects of the program that they
disliked, such as: Stimulus control (n = 2), sleep restriction (n = 1), sleep medication information
(n = 1), and relaxation techniques (n =1). Additional recommendations included: To extend
TeleCBT-I from four to six sessions (n =1), to include more relaxation techniques (n =1), and to
offer CBT-I sooner, or right after a cancer diagnosis (n = 2).
These results underscore patients’ overall high satisfaction with TeleCBT-I, and pointed
three valuable recommendations: (1) to extend the TeleCBT-I to spread-out the information and
allow more time to learn and practice the behavioral, cognitive and relaxation techniques, (2) to
improve the self-monitoring logs by making them more user-friendly, and (3) to increase access
to CBT-I by increasing dissemination efforts from the time of cancer diagnosis and throughout
the cancer care continuum.

70

Intent to Treat Results
Intent to treat analyses were conducted using the full analysis set, which includes two
patients that dropped out the study after completing pre-treatment measures and two patients
who did not complete treatment. The last observation carried forward imputation method was
used to assign post-treatment values. The tables presented in Appendix K detail the ITT results.
Overall, per protocol analysis produced similar findings as the intention-to-treat analysis,
increasing the confidence in the study results (Moher et al., 2010). As observed in the main
results as per-protocol, there were no differences between treatment groups on any of the
demographic and cancer related information at pre-treatment, except for personal income (p =
.042). Similarly, no differences were found on sleep and psychological measures at pre-treatment
between the TeleCBT-I and Control groups (ps >.05).
Although the results from the repeated measures analyses of variance followed the same
pattern as the per-protocol results, two differences were found. The Group effect on
dysfunctional beliefs about seep (DBAS-16) was found not statistically significant as per ITT
analyses, F(1, 37) = 2.56, p = .118, partial 2 = .065, while functional physical well-being
reached statistically significant values, F(1, 37) = 4.57, p = .039, partial 2 = .110.
Feasibility analyses were not computed because this was only assessed at post-treatment.
In sum, the ITT analyses revealed similar patterns as the as per-protocol analyses. Thus, ITT
results demonstrated that the per-protocol results represent unbiased treatment effects.
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CHAPTER FIVE: DISCUSSION
The current study tested the efficacy and feasibility of a brief telephone-delivered CBT-I
program for the treatment of insomnia in cancer patients compared to a treatment-as-usual
control group. The main study hypotheses that patients in the TeleCBT-I group compared to
control would report beneficial changes in all sleep variables immediately after treatment and
that these changes would be maintained at one-month follow-up were supported.
Patients in the TeleCBT-I group reported reduced insomnia severity, improved sleep
quality and decreased dysfunctional sleep beliefs at post-treatment and one-month follow-up.
Additionally, most patients in the TeleCBT-I group discontinued sleep medications at posttreatment, increasing the potential of experiencing less side effects and incurring in additional
treatment costs. These findings are consistent with prior research supporting the effectiveness of
CBT-I in patients with cancer compared to a treatment-as-usual control group (Bastien et al.,
2004; Espie et al., 2008). Indeed, the magnitude of effects found at post-treatment for TeleCBT-I
are comparable to those found in a recent meta-analysis for insomnia severity score (ISI)
(Johnson et al., 2016). Further, these findings are also similar to studies examining CBT-I in
cancer populations, providing further evidence of the effectiveness of CBT-I in cancer patients
(Casault et al., 2015; Dirksen & Epstein, 2008; Espie et al., 2008; Matthews et al., 2014; Zhou,
Partridge, Syrjala, Michaud, & Recklitis, 2017)
The hypothesis that TeleCBT-I would also have positive effects on fatigue, depression,
anxiety, functioning, and quality of life was partially supported. Although patients in the
TeleCBT-I group indicated greater improvements in fatigue compared to control at posttreatment, there were no time and group effects. However, results showed a statistically
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significant interaction effect at post-treatment and follow-up, indicating significant differences
between treatment groups and over time on fatigue. Further, patients in the TeleCBT-I group
reported lower scores and reached subclinical levels at post-treatment, while patients in the
control group reported slightly higher and clinical levels of fatigue at post-treatment.
Among cancer patients, fatigue is one of the most common complaints resulting from
cancer treatment (Donovan, Jacobsen, Small, Munster, & Andrykowski, 2008). However, its
presence and impairment are highly influenced by the course and type of cancer treatment that
patients undergone. It is possible that fatigue may stay constant during the course of cancer
treatment, and TeleCBT-I treatment improved patients’ ability to cope with fatigue over time.
Thus, improved perceived sleep quality and overall sleep, may increase a person’s ability to cope
with fatigue. Alternatively, changes in cancer treatments and recurrence in cancer symptoms may
dilute TeleCBT-I treatment effect as this study did not exclude patients based on type or current
cancer treatment. And therefore, patients could have experienced changes during the course of
TeleCBT-I treatment. Nonetheless, the impact of CBT-I on fatigue in this study was similar as
found in previous studies with cancer patients (Dirksen & Epstein, 2008; Heckler et al., 2016;
Johnson et al., 2016). However, more research is needed to determine what aspects of CBT-I
better target fatigue in cancer patients.
Importantly, both treatment groups reported normal to subclinical symptoms of anxiety
and depression at pre-treatment. As a result, this study was unable to examine whether TeleCBTI is also helpful to address anxiety and depressive symptoms. Nonetheless, while depressive
symptoms remain the same in the TeleCBT-I group, a slight reduction of anxiety symptoms was
observed at post-treatment in both treatment groups, suggesting that TeleCBT-I does not produce
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negative effects on anxiety and depression. Alternatively, it is possible that TeleCBT-I has no
effect on anxiety and depressive symptoms in cancer patients, and thus, the reduction of
symptoms may be an artifact of the natural decline often observed in mental health symptoms.
Previous research provide mixed evidence on the impact of CBT-I in other psychological
variables, such as fatigue, anxiety and depression (Quesnel et al., 2003; Savard et al., 2016;
Tremblay et al., 2009). This study provides further support of the need to investigate which
aspects of CBT-I address anxiety and depressive symptoms and whether the same aspects apply
to cancer patients.
Moreover, patients in the TeleCBT-I showed significant improvements in general
functioning, physical well-being, functional well-being, and physical quality of life compared to
those in the control group at post-treatment. However, treatment gains were only sustained at
one-month follow-up in the functional subscale of general functioning and the physical subscale
of quality of life. Importantly, these findings suggest that TeleCBT-I has a positive effect on
daily functioning and physical quality of life in patients with cancer whose daily functioning and
physical health is often significantly deteriorated during and after cancer treatment. Thus, these
findings suggest the CBT-I may be beneficial to cancer patients as improvement in sleep may
result in improvements in other aspects of physical health.
Overall, post hoc analyses revealed substantial changes across all time points. As
expected, patients in the TeleCBT-I group demonstrated significant changes from pre-treatment
to follow-up, but not from post-treatment to follow-up in all sleep measures. A further
examination of the means indicated that these changes were all indicative of reduction of
insomnia symptoms. Effect sizes (Hedges’ g) between pre-treatment and follow-up were all large
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(.84 – 2.7). These results suggest that TeleCBT-I is a viable option for treating insomnia in
cancer patients. Additionally, patients in the TeleCBT-I group reported statistically significant
improvement in fatigue, functional well-being, and physical QOL from pre-treatment to followup, suggesting that TeleCBT-I contributed to improvements in their perception of physical health
and daily functioning.
As expected the control group showed no significant changes from pre-treatment to
follow-up and from post-treatment to follow-up on all sleep and psychological measures, except
for insomnia severity and physical well-being. That is, a statistically significant decline was
observed in insomnia severity from pre-treatment to follow-up and from post-treatment and
follow-up in the control group. In terms of physical well-being, only the increase of scores from
post-treatment to follow-up was statistically significant. It is possible that these results in the
control group are attributable to the typical improvement observed in mental health symptoms
over time.
In terms of feasibility, previous research using telehealth modalities, provide encouraging
evidence to further examine whether telephone calls, which are an inexpensive means of
communication, can be used to provide evidence-based interventions, such as CBT-I. Indeed,
this study demonstrated that telephone-delivered CBT-I produces similar improvements in
insomnia symptoms as face to face delivered modalities. Overall, patient adherence was high
(90%) and most patients completed all required treatment sessions. Additionally, patients
reported high satisfaction with TeleCBT-I and indicated that they would highly recommend it to
other cancer patients. Together, these results indicate the telephone-delivered CBT-I is not only
effective at reducing insomnia symptoms, but also feasible in patients with cancer.
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Strengths
Based on the existing literature, this is the first study that tests telephone-delivered CBT-I
in a sample of patients with cancer. A major strength of this study was the randomized controlled
design that followed the CONSORT guidelines (Moher et al., 2010) and compared the treatment
group to a control group. Further, this study attempted to reflect the reality of clinical practice by
using a limited exclusion criterion and therefore allowing patients with different types of
diagnoses and stages of cancer to participate in the study. Additionally, patients were allowed in
the study regardless of the cancer treatment they were undergoing. Current sleep medication was
also allowed as many patients with cancer are prescribed sleep medication during cancer
treatment. Another strength was the use of well-defined diagnostic criteria.
Although the main goal of the study was to test the use of telephone communication as a
platform to provide CBT-I, patients were required to complete an in-person diagnostic interview
to assess current insomnia symptoms and other co-morbid mental health conditions. The newly
developed DSM-5 sleep module was used to determine insomnia diagnosis based on the DSM-5
criteria. Outcome measures were selected based on existing recommendations for insomnia
research facilitating future replication and comparison of results with previous research. Another
strength of the study is the use of an adapted CBT-I multicomponent program making it more
relevant to the study population. Lastly, treatment and assessments were conducted over the
telephone extending the use of telehealth to data collection practices and providing patients with
a consistent platform throughout their involvement in the study.
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Limitations
Although the innovative aspects of this study advance the evidence of CBT-I and its
dissemination and implementation via telephone-delivery in a sample of cancer patients, the
most notable limitation is the small sample size. Although sample size satisfied the minimal size
requirement for the purpose of this study, future research should involve larger sample sizes in
order to increase the statistical confidence of the results. Further, although the study included a
wide range of cancer diagnoses, the small sample limited the ability to examine group
differences based on type of cancer diagnosis and other variables of interest, such as age,
race/ethnicity, cancer stage, and use of sleep medications. Additionally, some of the measures
indicated a low reliability, which could be an effect of the combination of small sample size and
small number of items.
In terms of sleep indicators, the study did not assess sleep onset latency, total sleep time,
time awake after sleep onset, sleep efficiency and number of awakenings throughout the course
of TeleCBT-I and across all time points. These measures provide a more detailed
characterization of sleep patterns. Additionally, no objective sleep measures were used in the
study. Although insomnia is diagnosed based on patients’ perception of their sleep disturbance,
daytime symptoms, and impairment in daily functioning, actigraphy and polysomnography
identify other sleep problems (e.g., sleep apnea) that may be causing the underline sleep
disturbance. Thus, this study is unable to confidently assert that the sample had only diagnosable
insomnia with no presence of other sleep condition.
Treatment integrity as provided by three different clinicians was not assessed. However,
clinicians were supervised by a licensed clinical psychologist and followed a manualized
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program. In addition, patients received the same TeleCBT-I workbook, which provided
instructions and information that guided each session. Nonetheless, larger trials would benefit
from including fidelity measures.
The control group was deemed as treatment-as-usual, instead of a wait-list control group
because patients and providers were allowed to make changes to sleep medications throughout
the course of the study. Typically, wait-list control group are not offered or allowed any
treatment associated with the researched treatment. Thus, it is possible that patients in the control
group were actively using sleep medications or initiated or discontinued their sleep medication
during the course of the study making significant changes in their perception of sleep problems.
However, the study did assess for engagement in non-pharmacological treatments for insomnia
at post-treatment and follow-up and this was considered a reason for discontinuation in the study.
Although the study provides evidence for sustained effects on insomnia improvement at
one-month follow-up, future research investigating the effects of TeleCBT-I in cancer patients
over extended periods of time are needed. Lastly, the findings of this study are not generalizable,
but provide preliminary evidence for the efficacy and feasibly of using telephone calls to provide
a brief program of CBT-I in patients with cancer. Although the TeleCBT-I group reported
significant and sustained improvements in their sleep, more research is needed to understand
among patients with cancer, who does and does not benefit from CBT-I delivered via telehealth
platforms.
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Conclusion
Insomnia can be treated successfully in cancer patients using telephone-delivered CBT-I.
The four-week CBT-I program adapted for cancer patients led to decreased insomnia severity,
improved sleep quality and reduced dysfunctional thoughts about sleep in patients with cancer
with sustained gains observed at one-month follow-up. TeleCBT-I may have a positive impact
on fatigue, anxiety, functioning and quality of life, but more research is needed. Lastly,
telephone-delivered CBT-I is feasible and highly accepted among cancer patients.
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Sleeping Well Study: Evaluating Format Efficacy for Cognitive-Behavioral
Therapy for Insomnia in Adult Cancer Patients
Sleep Problems among Cancer Patients
 Sleep disturbances are among the most common and distressing symptoms endorsed by
cancer patients.
 Up to 80% of cancer patients experience sleep disturbances, while up to 60% suffer from
insomnia.
 The 2016 guidelines of the National Comprehensive Cancer Network (NCCN) and the
American College of Physicians (ACP) recommend the screening and assessment of sleep
complaints and treatment of insomnia during routine cancer care.
 The NCCN and ACP recommend that all adult patients with cancer and comorbid insomnia
symptoms receive Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first line of
treatment.
Challenges to Providing CBT-I to Cancer Patients
 Insomnia is often untreated and when treatment is offered, it generally entails medication
only.
 CBT-I is under-utilized and under-researched in cancer populations.
 Barriers include a lack of trained providers, commute to treatment centers, and treatment
duration.
The Sleeping Well Study will address these challenges by providing a brief CBT-I intervention
tailored to cancer patients via telephone! Participants will be randomized to either one of three
groups: (1) individual telephone sessions, (2) group telephone sessions or (3) a wait-list control
group. The CBT-I intervention consists of 3-4 sessions delivered 1 per week and over 1 month
period. Participants will also be followed at 3 and 6-month after treatment.
For more information, please contact Andel Nicasio at 321-841-5056/Andel.Nicasio@orlandohealth.com
.
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Sleeping Well: Telephone Script
Phone Script for Screening for Leaving Voicemail #1
This message is for ____. This is ____ from the Cancer Support Community at Orlando
Health. I’m calling to tell you about our Sleeping Well research study we are running here at the
center. The study will be evaluating a brief talk therapy program tailored for adult cancer patients
experiencing sleep problems. This form of talk therapy, called CBT, is the recommended
treatment for sleep problems, but can also help reduce fatigue, anxiety and depression, and
improve overall quality of life. It only requires one in-person visit with the rest of the study
completed over the phone. We are currently seeking participants, so if you’d like to learn more
about this study, please give us a call back at 321.841.5056. Thank you and have a great day.
Phone Script for Screening for Leaving Voicemail #2
This message is for ____. This is ____ from the Cancer Support Community at Orlando
Health. I’m calling to find out if you might be interested in participating in a study evaluating a
brief talk therapy program tailored for adult cancer patients experiencing sleep problems. This
study is conducted over the phone and only requires one in-person visit to get started. If you’d
like to learn more about this study, please give us a call back at 321.841.5056. Thank you and
have a great day.
Phone Script for Screening for Leaving Voicemail #3
This message is for ____. This is ____ from the Cancer Support Community at Orlando
Health. The reason for my call is to tell you about a Sleeping Well study we are conducting
where we will be providing a brief talk therapy program for sleep problems in adult cancer
patients. This study only requires one in-person visit with the rest completed over the phone.
This is the final phone call to you regarding this study, so if you are interested in learning
more about it, please give us a call back at 321.841.5056. Thank you and have a great day.
Phone script for Live Call
Hi. Is this ___? My name is ___ and I’m calling from the Cancer Support Community at
Orlando Health. How are you today? [open response]. I’m calling today to tell you about our
Sleeping Well Study that we’re conducting through the center and I wanted to find out if you’d
be interested in possibly participating.
[If No] – Ok. Just to let you know, the Cancer Support Community offers a variety of
free support including mindfulness workshops, yoga, art & crafts, and support groups. We invite
you to stop by and say hello.
[If Yes] OK Great, so this study will be using talk therapy tailored for cancer patients to
help reduce sleep problems. We will be using Cognitive-Behavioral Therapy, also called CBT
which is a form of talk therapy that has been recommended for treating sleep problems,
particularly insomnia but it can also help with fatigue, anxiety, depression, and overall quality of
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life. Basically, we will be evaluating the effectiveness of CBT treatments provided over the
phone.
The study starts with a brief phone screening to see if you qualify. If you qualify, we will
set up your in-person interview where we further evaluate sleep problems and any other
emotional issues. You’ll only need to attend this one interview as the rest can be completed over
the phone. You will be randomly assigned to one of three groups. Group 1 will receive individual
treatments over the phone; Group 2 will receive CBT-I treatments in a group conference call
format; and group 3 will be waitlisted but given the option to receive CBT-I treatment over the
phone or in person. The study includes 3 to 4 phone therapy sessions and a 1, 3, and 6 month
follow-up phone call interview, each lasting approximately 1 hour.
Participation is completely voluntary and at no cost to you. Your participation in this
study will not affect your current treatment at UF Health Cancer Center - Orlando Health. Do
you have any questions about the study?
Would you be interested in participating in this study?
- If Yes… Proceed with the screening information.
- If No… Thank Her/Him for her/his time. End of contact.
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Sleeping Well Study: Telephone Screening
1. Are you 18 years old or older?
If Yes… Continue. | If No… Discontinue.
2. Are you a cancer patient?
(Cancer patient could be any one with a diagnosis of cancer stages I-IV and who
is receiving treatment or has recently completed treatment (< less than 5 years after
completing treatment or that the person is in complete remission)
If Yes… Continue. | If No… Discontinue.
3. Are you a patient at Orlando Health UF Health Cancer Center?
If Yes… Continue. | If No… Discontinue.
4. Do you currently have trouble sleeping?
If Yes… Continue. | If No… Discontinue.
5. Have you ever been diagnosed with Sleep apnea?
If Yes… Ask if S/He is currently receiving treatment for Sleep Apnea.
- If Yes, continue. | - If No… Discontinue.
If No… Continue.
6.

Have you ever been diagnosed with Restless Legs Syndrome (RLS)?
If Yes… Ask if S/He has a current diagnosis of RLS and if S/He is currently
receiving treatment for RLS.
- If Yes for either question above … Discontinue.
If No… Continue.

7. Have you been diagnosed with Periodic Limb Movement Disorder (PLMD)?
If Yes… Ask if S/He has a current diagnosis of PLMD and if S/He is currently
receiving treatment for PLMD.
- If Yes for either question above… Discontinue.
If No… Continue.
8. Have you been diagnosed with Narcolepsy?
If Yes… Ask if S/He has a current diagnosis of Narcolepsy and if S/He is
currently receiving treatment for Narcolepsy.
- If Yes to either question above … Discontinue.
If No… Continue.
9. Are you able to attend an interview session at UF Health Cancer Center-Orlando
Health, Integrative Medicine Department?
If Yes… Continue. | If No… Discontinue.
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10. Are you able to attend 3-4 sessions, one per week, over the telephone?
If Yes… Continue. | If No… Discontinue.
Okay. Thanks for answering these questions. Now, I am going to ask you more specific
questions about your sleep. We are almost done with the phone screening.

SQD Administration


QUALIFIES IF: Score of 3, 4 or 5 in any questions indicates possible insomnia or sleep
problems.
We’ve finished the screening now, and you qualify for the study. The next step is to
schedule the appointment for the in-person interview. This interview will further evaluate
your eligibility and ask more questions about your sleep and potential emotional problems.
You will also be assigned to one of the 2 groups.
Schedule Intake Appointment (in-person). Thank Her/Him for their time and
provide the Cancer Support Community telephone number (321-841-5056) to call back if
S/He has any questions.


DOES NOT QUALIFY IF: Scores of 1-2 in all questions. Discontinue. Explain
participant that S/He is not eligible for this study, but that S/He is welcome to enroll in
other studies at UF Health Cancer Center-Orlando Health for which S/He qualifies in the
future. Thank Her/Him for her/his time.
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Sleeping Well Study
Sleep and Demographic Information
All information on this sheet is strictly confidential.
Date: _______________
Contact Information:
Last Name: ______________________ First Name: ___________________ Middle Initial: ____
Address: ______________________________________________________________________
Phone: ___________________________ Is it Okay to leave voice messages?  Yes  No
Email: __________________________________________
Emergency Contact: ___________________________ Phone Number: ____________________
Relationship to Emergency Contact: ________________________________________________
Referring Physician or Medical Provider: _______________________________________

Sleep Information
What is your main sleep complaint? ____________________________________________
___________________________________________________________________________
___________________________________________________________________________
Past Sleep Evaluation and/or Treatment:
 I have had a previous sleep disorder evaluation
 I have been prescribed PAP for home use
 I wear oxygen at night
 I have had a previous overnight sleep study
 I have had surgical treatment for a sleep disorder
 I have a family member with sleep apnea
Please list
1) Date of Prior Sleep Study: _______________
2) Diagnosis: ____________________________
3) Treatment if applicable: ____________________________
Duration of Symptoms: _______________months / years
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Have you received any treatment for sleep problems?
 Yes  No
If yes, please indicate below:
 Medication
 Relaxation techniques
 Psychotherapy
Other. Please describe: __________________________________________________________

Sleep Habits
 I usually watch TV in bed prior to sleep
 I usually read in bed prior to sleep
 I eat a snack at bedtime
 I work a rotating shift or I am a shift worker
 I smoke prior to bedtime or when I awaken during the night
 I eat if I wake up during the night
 I often travel across two (2) or more time zones
 I drink alcohol in the evening time to help get to / stay asleep

Bedroom Habits
 I sleep alone
 I share a bed with someone
 I share a dwelling but have separate bedrooms
 I share the bed with pets
 I have an uncomfortable bed or pillow
 I have an uncomfortable temperature in the bedroom
 I have a noisy bedroom or have too much light in the bedroom
 I have too many electrical devices in the bedroom

Sleep Pattern:
Typical bedtime ______________________ AM/PM
How many minutes to fall asleep _________________________
How many awakenings in the night? _____________
Do you fall back to sleep easily? Yes  No
Typical wake-up time ________________ AM/PM
Do you nap? Yes  No
If yes, when / how long _______________
Other relevant Information about Sleep:
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
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Cancer Diagnosis Information
With which type of cancer were you diagnosed?
 Breast cancer
 Melanoma
 Lung cancer
 Non-Hodgkin’s Lymphoma
 Non-Melanoma skin cancer
 Thyroid cancer
 Melanoma skin cancer
 Kidney cancer (renal cell)
 Prostate cancer
 Leukemia
 Bladder cancer
 Pancreatic cancer
 Colon cancer
 Endometrial cancer
 Pharyngeal (Throat cancer)
 Other Please specify: _________________________________________________________
How long ago were you diagnosed with cancer?
 Less than 1 year ago
 1 year ago to 2 years ago
 2 years to 5 years ago
 _____________________ Include date if known or provided
At what stage were diagnosed?
 Stage I
 Stage II
 Stage III
 Stage IV
 Limited Stage
 Extensive Stage
Which of the following best describes your current condition?
 My stage has remained the same
 My stage has increased
 I am cancer free
Have you ever undergone any of the following cancer treatments to help reduce or control
the spread of your cancer? (Check all that apply)
 Chemotherapy
 Radiation therapy
 Hormonal therapy
 Surgery
 Targeted drug therapy (Treatment targets changes in cancer cells)
 Stem cell transplant
 Clinical trial
 I have not undergone any cancer treatments
 Other. Please specify: _________________________________________________________
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What type of cancer treatment are you currently receiving? (Check all that apply / See
Next Page)
 Chemotherapy
 Radiation therapy
 Hormonal therapy
 Surgery
 Targeted drug therapy (Treatment targets changes in cancer cells)
 Stem cell transplant
 Clinical trial
 No cancer treatment at this time
 Other. Please specify: _________________________________________________________

When do you expect to complete your current cancer treatment? (If applicable)
______________________________________________________________________________

Are you using any other healing methods? Please check all that apply
 Acupuncture
 Massage Therapy
 Chiropractor
 Medical Doctor
 Energy Healing
 Mental Health Professional
 Physical Therapist
 Music or Art Therapy
 Other. Please describe: _______________________________
Mental Health History
Have you ever been diagnosed with a mental illness?
Yes  No
If yes, please indicate diagnosis: ___________________________________________________
Have you ever been hospitalized in relation to mental health?
Yes  No
If yes, please describe: ___________________________________________________________
Pain
On a scale of 0 (no pain) to 10 (extreme pain),
A.
What is your level of pain right now? ________
B.
What has your average pain level been over the past month? _________
Have you had a recent surgery (within the past 6 months)
Yes  No
If yes, please describe: ___________________________________________________________
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Caffeine intake
Do you consume caffeine?  Yes
If Yes, do you consume  Coffee

 No
 Caffeinated drinks

 Caffeine pills

Estimate average cups of coffee per day? _________________ Oz/ Cups
On a typical day, when do you drink coffee?
 Morning (6am-noon)
 Afternoon (noon-6pm)
 Evening 6pm-2am)
(2am-6am)

 Night

Sodas, tea, Jolt®, Mountain Dew®, Red Bull ®, Monster®, ROCKSTAR Energy Drinks®
Estimate average number of caffeinated drinks per day? _________________ Oz/ Drinks
On a typical day, when do you drink caffeinated drinks?
 Morning (6am-noon)
 Afternoon (noon-6pm)
 Evening 6pm-2am)
 Night
(2am-6am)
Tobacco Intake
Have your ever smoked?
 Yes  No
If Yes, how long have you smoked? ___________ Years
How much? _________________Number of cigarettes/Day (1 pack has 20 cigarettes; Export As
has 25)
Have you quit smoking?
 Yes  No
If Yes, Year Quit __________________
If No, do you use cigarettes, smokeless tobacco, snuff, or other tobacco products?
__________________________________________________________________
How much per day? __________________________
Alcohol Intake
Do you drink Alcohol?
 Yes  No
If Yes, how much do you drink? ___________ drinks
How frequent?
 Daily  Weekly (_______times per week)  Socially ______________
What kind of alcohol?
 Beer
 Liquor
 Wine
Do you drink alcohol before going to bed frequently?
 Yes  No
Do you use any other substances?  Marijuana  Cocaine  Crack  Other: ________
Do you use of these substances to help fall asleep or take it before going to bed?  Yes  No
Exercise
Do you exercise?
 Yes  No
If Yes, how frequently? _________________________________
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Other Health History
Have you been diagnosed with a chronic or severe health condition? Please check all that
apply.
 Asthma
 Back Pain
 Arthritis
 Chronic fatigue syndrome
 Diabetes
 Multiple Sclerosis
 Heart Condition
 High/Low Blood Pressure
 Headaches/Migraine

 Eating Disorders
 ADHD
 Anxiety
 Bipolar Disorder
 Depression
 Panic attacks
 PTSD
 Schizophrenia
 Other, please specify: _________________________

Current Medication
Please list all your current medications
Prescription Medication Name

How much?

How often?

Last taken?

Over-the-counter Medication Name

How much?

How often?

Last taken?

Herbal Remedy / Nutritional
Supplement Name

How much?

How often?

Last taken?
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General Demographic Information
Age: _______ DOB: _______________
Gender:
 Female

 Male  Other. Please specify: _________________________

What is your height? ___________ Feet ________Inches
What is your weight today? ________ Weight one year ago? ________
Marital Status:
 Married
 Single
 Divorced  Life Partner  Separated  Widowed
 Other. Please specify: ________________________________
Race/Ethnicity:
 Asian/Pacific Islander
 Black or African American
 Hispanic or Latino
 Middle Eastern (Arabs, Turks, Persians, Jews, etc.)
 Native American or Alaska Native
 South Asian (India, Pakistan, Bangladesh, Nepal, etc.)
 White
 Other. Please specify: ____________________________
Employment Status
 Active Duty Military
 Disabled
 Employed Full-Time
 Employed Part-Time
 Homemaker

 Not Employed
 Retired
 Self Employed
 Student Full-Time
 Student Part-Time
 Other. Please specify: _________________

Highest Level of Education
 No schooling completed
 Some school, but less than 8th grade
 Completed 8th grade
 Some high school, no diploma
 High school graduate, diploma or the equivalent of GED
 Some college, no degree
 Trade/technical school/vocational training
 Associate degree
 Bachelor’s degree
 Master’s degree
 Professional degree
 Doctorate degree
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Personal Annual Income
 Less than $15,000
 $15,000 – $24, 999
 $25,000 – $34,999
 $35,000 – $49,999
 $50,000 – $74, 999
 $75,000 or more
 Does not apply

Household Annual Income
 Less than $15,000
 $15,000 – $24, 999
 $25,000 – $34,999
 $35,000 – $49,999
 $50,000 – $74, 999
 $75,000 or more

Religious Preference
 Atheism/Agnosticism
 Buddhism
 Catholicism
 Christianity
 Hinduism
 Judaism
 Mormonism
 Islam
 Orthodox Church such as Greek or Russian Orthodox Church
 Protestantism
 Seventh-Day Adventists
Other. Please specify: _____________________________________________

For Research Personnel Only
Referral Date: ______________ By: _________________________
Med approval date: ___________________
Eligible: (Y/N): _____________________ Exclusion reason (if applicable): ________________
Consented: (Y/N): ______________________ Date: __________________
Randomization group: ___________________
Screening Date: ___________________
Baseline date: ____________________
Sleep Diary Start Date: _______________
Session 1: Date: ___________ Attendance (Y/N): _______
Session 2: Date: ___________ Attendance (Y/N): _______
Session 3: Date: ___________ Attendance (Y/N): _______
Session 4: Date: ___________ Attendance (Y/N): _______
Post-Assessment Date (scheduled): _________________ Completion date: ________________
1 MONTH FU Date (scheduled): ___________________ Completion date: ________________
3 MONTH FU Date (scheduled): ___________________ Completion date: ________________
6 MONTH FU Date (scheduled): ___________________ Completion date: ________________
Lost to contact: (Y/N): ______ Date of last contact: _____________________
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Research Study:
Sleeping Well: Evaluating Format Efficacy for
Cognitive-Behavioral Therapy for Insomnia in Adult Cancer Patients
Request for Release to Participate
Orlando Health | UF Health Cancer Center (“UFHCC”), Integrative Medicine Department is
conducting a research study to investigate the effects of a brief Cognitive-Behavioral Therapy
(CBT) for sleep problems tailored for cancer patients. CBT is a form of talk therapy and is the
recommended treatment for sleep problems, particularly insomnia.
About the study:
 This is a 4-week program delivered once a week over the telephone.
 Before starting the program participants attend an in-person interview to further evaluate
sleep problems and any other emotional issues.
 Participants are randomized to participate in one of three groups: Group A receives the
intervention via individual telephone calls, Group B receives the intervention via group
telephone conferences, and Group C receives treatment as usual and is given the option to
receive the intervention in a few months either in-person or by telephone.
 Follow-up assessments are collected via telephone at 1, 3 and 6 months after end of
program.
By signing below, I acknowledge/represent the following:
I desire to participate in the Sleeping Well study (ORMC IRB# 10.002.01). I understand that
during my participation I will be asked about personal matters regarding my sleep patterns. It is
possible that I may feel tired, upset or anxious. If this happens, you can choose not to answer any
or all the questions. Additionally, a clinician is available to speak to you. I certify that I
voluntarily applied to participate in the study and am cognizant of all of the inherent dangers and
risks that Cognitive Behavioral Therapy for sleep problems could offer to me.
My physician is signing below only to acknowledge that I am able to engage in cognitive
behavioral therapy, and that I am able to consent to participation in the study. In the event I have
any questions or concerns about my health before, during, or after my participation in the study, I
am responsible to seek appropriate medical attention.
As I understand my participation in the Sleeping Well study is voluntary, I agree to release
UFHCC and anyone associated with these organizations (the “Released Parties”) from all claims
and damages that may occur due to my participation in the study.
Participant
Signature: __________________________
Print:______________________________
Date: ______________________________

Physician
Signature: __________________________
Print: ______________________________
Date: ______________________________
111

APPENDIX I: TREATMENT SATISFACTION QUESTIONNAIRE

112

Sleeping Well: Treatment Satisfaction Questionnaire
Thank you for participating in the Sleeping Well Study. Please answer the following
questions as honestly and accurately as possible. We appreciate your thoughtful feedback, as it
will help us evaluate the effectiveness of Sleeping Well Program and help us make it even better
for future participants!
Next to each statement below, please put a mark (X) to show whether you “strongly
agree”; “agree”; “disagree”; or “strongly disagree” with the statements below.

Section 1: Your treatment Experience [Card # 47]
Strongly
During my contact with this treatment . . .
Agree (3)

a. The program has motivated me to work on my
sleep problems.
b. I did not like all the program sessions I attended.
(reversed)
c. I did not have enough time to talk about my own
sleep problems. (reversed)
d. I have not liked some of the program rules or
regulations. (reversed)
e. I did not find it convenient to participate in the
program via telephone. (reversed)
f. I felt safe and comfortable talking about my sleep
problems.
g. I am satisfied with the accomplishments or
changes I have made to improve my sleep.
h. I have learned one or more strategies to improve
my sleep.
i. I gained greater understanding of my sleep
problem(s).
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Agree
(2)

Disagree
(1)

Strongly
Disagree
(0)

Strongly
Agree (3)

Section 2. Questions about the practitioner

Agree
(2)

Disagree
(1)

a. The practitioner understood my sleep
problems and concerns.
b. The practitioner gave me as much
information as I wanted about what I could
do to manage my sleep problems.

c. The practitioner was good at her/his job.

d. I was treated considerately and respectfully
by the practitioner.

Section 3: Overall Service Experience
1. How many sessions did you complete? __________
2. Overall, how satisfied or dissatisfied are you with the Sleeping Well Program?
 Very satisfied (4)
 Somewhat satisfied (3)
 Neither satisfied nor dissatisfied (2)
 Somewhat dissatisfied (1)
 Very dissatisfied (0)
3. Overall, how helpful or unhelpful was the program manual?
 Very helpful (4)
 Somewhat helpful (3)
 Neither helpful nor unhelpful (2)
 Somewhat unhelpful (1)
 Very helpful (0)
4. Overall, how often did you practice the suggested homework or daily practice?
 Daily (4)
 Almost daily / Most days (4-6 days per week) (3)
 Occasionally (1-3 days per week) (2)
 Rarely (0-1 days per week) (1)
 Never (0 days per week) (0)
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Strongly
Disagree
(0)

5. How likely are you to suggest the Sleeping Well Program to another cancer patient?
 Extremely likely (4)
 Very likely (3)
 Somewhat likely (2)
 Not so likely (1)
 Not at all likely (0)
6. What did you find most helpful about the Sleeping Well Program?
________________________________________________________________________
________________________________________________________________________
7. What did you find least helpful about the Sleeping Well Program?
________________________________________________________________________
________________________________________________________________________
8. Please rate your overall experience with the Sleeping Well Program.
0
1
Very
Dissatisfied

2

3

4

5

6

7

8

9

10
Very
Satisfied

9. Do you have any additional comments, suggestions or concerns?
__________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________
Section 4. Physical health and Life Changes
Have you experienced any changes in your cancer treatment over the past month?
 No  Yes; if Yes, please explain:
____________________________________________________________________
Have you experienced any changes in your medication over the past month?
 No  Yes; if Yes, please explain:
____________________________________________________________________
2a.What about Sleep medications? Any changes over the past month?
____________________________________________________________________
____________________________________________________________________
Have you been diagnosed with a new condition over the past month?
 No  Yes; if Yes, please specify:
____________________________________________________________________
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Aside from participating in the Sleeping Well Program, have you participated in another
sleep program over the past month?
 No  Yes; if Yes, please specify:
____________________________________________________________________
Have you experienced any major life changes over the past 2 months?
 No  Yes; if Yes, please review the list below and let us know which event and how much
the event has affected your life by circling the appropriate number.

Event
 Going back to work or a new job
 Being fired or laid off from work
 Major change in your home conditions or
living arrangements
 Separation or divorce from spouse or
partner
 Death of a loved one
 Family conflicts (e.g., parenting problems,
problems with in-laws or relatives)
 Change in your religious beliefs
 Loss or damage to personal property
 Took vacation
 Major change in finances (increased or
decreased)
Other? _____________________________

Type of effect

Effect of Event on Your Life

Good

Bad

Good
Good
Good

Bad
Bad
Bad

No
effect
0
0
0

Some
effect
1
1
1

Moderate
effect
2
2
2

Great
effect
3
3
3

Good

Bad

0

1

2

3

Good
Good

Bad
Bad

0
0

1
1

2
2

3
3

Good
Good
Good
Good

Bad
Bad
Bad
Bad

0
0
0
0

1
1
1
1

2
2
2
2

3
3
3
3

Good

Bad

0

1

2

3

Thank you! Please remember that we will be in contact with you to conduct the follow-up
assessments over the phone at 1, 3, and 6 months.

If possible, please schedule the next telephone assessments:
1 month follow-up appointment: ___________________________
3 month follow-up appointment: ___________________________
6 month follow-up appointment: ___________________________
End!!!
Thank you for taking the time to complete these questionnaires.
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Sleeping Well Study
[Date]
Dear ___________,
Thank you for being a participant in the Sleeping Well Study! Your participation will help
us learn whether telephone-based delivery of Cognitive-Behavioral Therapy for Insomnia is
effective and feasible for cancer patients. We hope your experience with us has been one of
positive learning and change. We wish you well in the unfolding moments of your life.
Remember to continue practicing the strategies and skills learned throughout the Sleeping
Well program. Your continued healthy sleep practices will help you to improve your sleep and
overall quality of life. If you would like to continue working on your sleep habits, we can help
you to set up an appointment through the Integrative Medicine Department for individual and
group therapy sessions. Furthermore, remember that you have access to many activities free of
charge through the Cancer Support Community, including mindfulness-based stress reduction
group, return to wellness group, yoga classes, and much more.
Below are some general suggestions for continued practice:
1. Keep a consistent sleep schedule.
2. Limit daytime naps to 30 minutes.
3. Avoid stimulants close to bedtime (e.g., caffeine, alcohol).
4. Exercise early and regularly to promote good quality sleep.
5. Stay away from food that can be disruptive right before sleep (e.g., fatty or fried meals,
spicy dishes).
6. Balance fluid intake before going to bed (i.e., enough to keep from waking up thirsty, but
not too much that you will be awakened by the need to go to the bathroom).
7. Ensure adequate exposure to natural light.
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8. Practice a relaxing bedtime routine.
9. Make sure that your sleep environment is pleasant.
10. Be positive! Think about positive thoughts before going to sleep or practice gratitude by
thinking about what you’re grateful for.

Your Change Scores
You completed assessments of sleep, fatigue, depression, anxiety and quality of life
before and after the program. The table below shows the change in your scores, whether for
better, worse or no change. We will provide you the scores for the follow-up sessions as well at
the end of the study in about six months.

Insomnia Severity
Sleep Quality
Sleep Efficiency
Depression
Anxiety

Before/Descriptor
_______________
_______________
_______________
_______________
_______________

After/Descriptor
_______________
_______________
_______________
_______________
_______________

Thank you for your time and participation in the Sleeping Well Study. Your participation
is valuable and very important to us. Please contact the Integrative Medicine Department for
further questions or information.
Integrative Medicine Department
Telephone: (321)-841-5056
Fax: (321)-843-6777
22 W. Underwood St., 2nd Floor, MP 710-10
Orlando, FL 32806
UFHealthCancerOrlando.com
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Intent to Treat Results
Table 11.
ITT Results for Demographic and Sample Characteristics by Treatment Group

Variables
Age (years)

TeleCBT-I
(n = 21)
Mean
SD
No
%
55.05
10.15
Range = 36 to 71

Control
(n = 18)
Mean
SD
No
%
52.28
12.32
Range = 29 to 74

p
.446

Sex
.647
Female
19
90.5
15
83.3
Race/Ethnicity
Non-Hispanic White
13
61.9
8
44.4
.142
African American
3
14.3
2
11.1
Hispanic
3
14.3
8
44.4
Mixed
2
9.5
Marital status
Single
3
14.3
5
27.8
.444
Married
7
33.3
9
50
Divorced
8
38.1
3
16.7
Widowed
3
14.3
1
5.6
Highest Level of Education
High School or GED
2
11.1
.079
Some College
5
23.8
6
33.4
Bachelor’s degree
7
33.3
8
44.4
Master’s degree
9
42.9
2
11.1
Employment
Part-time
2
9.5
2
11.1
.509
Full-time
9
42.9
6
33.3
Unemployed
3
14.3
2
11.1
Retired
7
33.3
5
27.8
Disabled
3
16.7
Income
Less than $15,000
3
14.3
5
29.4
.042*
15,000-24,999
3
14.3
3
17.6
25,000-34,999
4
23.5
35,000-49,999
4
19
50,000-74,999
5
23.8
1
5.9
75,000 or more
6
28.6
4
23.5
Note. Significance tests for continuous variables were determined with independent samples t-tests (2tailed), while Fisher’s exact tests were used for dichotomous and categorical variables. Income (n = 34).
Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; No,
Frequency; %, Percentage.
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Table 12.
ITT Results for Cancer Related Information by Treatment Group

Variables
Cancer stage
Stage I
Stage II
Stage III
Stage IV
Don’t know
Time since cancer diagnosis
Less than one year
One to two years ago
Two or more years ago
Cancer location
Breast
Brain
Skin
Colon
Head and Neck
Kidney
Musculoskeletal
Lung
Blood
Ovarian
Past cancer treatments
Chemotherapy
Radiation therapy
Surgery
Hormone therapy
No past treatment
Current cancer treatments
Chemotherapy
Radiation Therapy
Surgery
Hormone therapy
No current treatment

TeleCBT-I
(n = 21)
No
%

Control
(n = 19)
No
%

8
6
3
3
1

38.1
28.6
14.3
14.3
4.8

6
2
3
2
5

33.3
11.1
16.7
11.1
27.8

7
5
9

33.3
23.8
50

7
2
9

38.9
11.1
50

p
.327

.699

.541
14
2
1
1
1
1
1

66.7
9.5
4.8
4.8
4.8
4.8
4.08

8
3
2
1
2
1
1
-

44.4
16.7
11.1
5.6
11.1
5.6
5.6
-

16
15
15
11
-

76.2
71.4
71.4
52.4
-

10
11
14
5
1

55.6
61.1
77.8
27.8
5.6

.307
.734
.726
.192
.462

4
3
3
7
7

19
14.3
14.3
33.3
33.3

2
2
3
3
12

11.1
11.1
16.7
16.7
66.7

.667
>.05
>.05
.290
.056

Note. Differences by group were determined with Chi-square and Fisher’s exact tests.
Abbreviations: TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; No,
Frequency; %, Percentage.
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Table 13.
ITT Results for Sleep Measures and Group Differences at Pre-treatment

Variables

TeleCBT-I
(n = 21)
Mean
SD

Control
(n = 19)
Mean
SD

ISI
PSQI
DBAS-16
Sleep Medication % (n)

17.76
12
5.13
52.4

17.28
11.94
5.43
47.6

4.13
3.23
1.50
11

4.55
3.93
1.76
10

t (37) / 2

p

95% CI

.348
.048
-.576
.039

.730
.962
.568
> .05

[-2.33, 3.30]
[-2.27, 2.38]
[-1.36, 0.76]

Note. Significance tests were determined with independent samples t-tests (2-tailed) or chi-square tests.
Abbreviations: TeleCBT-I, TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; ISI,
insomnia severity inventory; PSQI, Pittsburgh sleep quality index; DBAS-16, dysfunctional beliefs about
sleep.

Table 14.
ITT Results for Psychological Measures and Group Differences at Pre-treatment
Variables

TeleCBT-I
(n = 21)
Mean
SD

Control
(n = 18)
Mean
SD

t (37)

p

95% CI

FSI
HADS-Depression
HADS-Anxiety
FACT General
Physical
Social/Family
Emotional
Functional
QOL-CSV Total
Physical
Psychological
Social
Spiritual

4.73
5.95
8.38
69.81
19.86
18.33
16.24
15.33
5.66
6.34
5.64
5.72
5.84

4.97
6.67
8.28
71.72
18.61
19.22
17
16.94
5.53
6.27
5.73
5.18
6.29

-.381
-.505
-.070
-.331
.808
-.449
-.453
-.875
.264
.126
-.134
.729
-.606

.705
.616
.945
.742
.424
.656
.653
.387
.794
.900
.894
.471
.548

[-1.53, 1.04]
[-3.58, 2.15]
[-2.89, 3.09]
[-13.62, 9.79]
[-1.89, 4.37]
[-4.90, 3.13]
[-4.17, 2.64]
[-5.34, 2.12]
[-0.85, 1.11]
[-1.02, 1.15]
[-1.42, 1.24]
[-0.95, 2.02]
[-1.93, 1.04]

1.63
4.91
4.69
19.91
4.87
6.39
6.02
6.61
1.63
1.62
2.39
2.11
2.53

2.31
3.71
4.48
15.40
4.72
5.90
4.12
4.49
1.35
1.71
1.56
2.47
1.95

Note. Significance tests were determined with independent samples t-tests (2-tailed).
Abbreviations: TeleCBT-I, TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; FSI,
fatigue symptom inventory; HADS-D, depression subscale of hospital anxiety and depression scale; HADSA, anxiety subscale of hospital anxiety and depression scale; FACT, functional assessment of cancer therapy;
QOL-CSV, quality of life patient/cancer survivor version.
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Table 15.
ITT Results on Sleep Measures by Each Group at Pre-treatment and Post-treatment and Treatment Effects

Variables
ISI
TeleCBT-I
Control
PSQI
TeleCBT-I
Control
DBAS-16
TeleCBT-I
Control

LMM Statistical Tests (Type III tests of fixed effects)
Group x Time
Time Effect
Group Effect
Interaction

Pre-treatment

Post-treatment

Mean

SD

Mean

SD

F(1, 37)

p

F(1, 33)

p

g

F(1, 33)

p

17.76
17.28

4.13
4.55

8.52
14.94

5.23
5.54

61.26

< .001

4.61

.038

1.19

21.81

< .001

12
11.94

3.23
3.93

6.62
11.39

3.29
4.06

32.13

< .001

4.17

.029

1.30

21.23

< .001

5.13
5.43

1.50
1.76

3.58
4.95

1.85
1.95

20.81

< .001

2.56

.118

.72

5.81

.021

Note. Between-group effect sizes were computed as Hedges’ g values.
Abbreviations: TeleCBT-I, TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; ISI, insomnia severity
inventory; PSQI, Pittsburgh sleep quality index; DBAS-16, dysfunctional beliefs about sleep.

124

Table 16.
ITT Results on Psychological Measures by Group at Pre-treatment and Post-treatment and Treatment Effects

Pre-treatment

Post-treatment

LMM Statistical Tests (Type III tests of fixed effects)
Group x Time
Time Effect
Group Effect
Interaction

Variables
Mean
SD
Mean
SD
F(1, 33)
p
F(1, 33)
p
g
F(1, 33)
p
FSI
TeleCBT-I
4.73
1.63
3.29
2.55
3.83
.058
3.24
.080
.88
9.95
.003
Control
4.97
2.31
5.31
1.98
HADS-Depression
TeleCBT-I
5.95
4.91
5.76
5.94
.001
.977
.397
.533
.21
.141
.710
Control
6.67
3.71
6.89
4.38
HADS-Anxiety
TeleCBT-I
8.38
4.69
7.14
4.01
5.83
.021
.009
.925
.03
.001
.970
Control
8.28
4.48
7
4.14
FACT General
TeleCBT-I
69.81
19.91
77.24
23.06
.347
.560
.515
.478
.49
6.33
.016
Control
71.72
15.40
67.11
17.18
Physical
TeleCBT-I
19.86
4.87
22.14
5.99
.002
.968
4.57
.90
8.05
.007
.039
Control
18.61
4.72
16.39
6.88
Social/Family
TeleCBT-I
18.33
6.39
19.81
6.59
.050
.825
.043
.837
.25
1.35
.254
Control
19.22
5.90
18.22
5.87
Emotional
TeleCBT-I
16.24
6.02
17.33
5.86
.750
.392
.007
.934
.10
1.39
.247
Control
17
4.12
16.83
4.15
Functional
TeleCBT-I
15.33
6.61
17.95
7.46
.702
.407
.036
.850
.36
5.93
.020
Control
16.94
4.49
15.67
4.67
Note. Abbreviations: TeleCBT-I, TeleCBT-I, telephone-delivered cognitive behavioral therapy for insomnia; FSI, fatigue symptom inventory;
HADS-D, depression subscale of hospital anxiety and depression scale; HADS-A, anxiety subscale of hospital anxiety and depression scale;
FACT, functional assessment of cancer therapy; QOL-CSV, quality of life patient/cancer survivor version.
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Table 17.
ITT Results on Quality of Life by Group at Pre-treatment and Posttreatment and Treatment Effects

Pre-treatment

Post-treatment

LMM Statistical Tests (Type III tests of fixed effects)
Group x Time
Time Effect
Group Effect
Interaction

Variables
Mean
SD
Mean
SD
F(1,33)
p
F(1,33)
p
g
F(1,33)
p
QOL-CSV Total
TeleCBT-I
566
1.63
5.93
1.86
.244
.624
.506
.481
.35
1.98
.167
Control
5.53
1.35
5.39
1.07
Physical
TeleCBT-I
6.34
1.62
7.46
1.34
1.86
.180
3.56
.067
1.08
14.47
.001
Control
6.27
1.71
5.74
1.84
Psychological
TeleCBT-I
5.64
2.39
6.17
2.33
1.49
.230
.089
.767
.23
1.56
.219
Control
5.73
1.56
5.72
1.28
Social
TeleCBT-I
5.72
2.11
5.97
2.42
.247
.622
.916
.345
.35
.348
.559
Control
5.18
2.47
5.16
2.22
Spiritual
TeleCBT-I
5.84
2.53
6.06
2.67
3.33
.076
.849
.363
.37
.729
.399
Control
6.29
1.95
6.89
1.59
Note. Abbreviations: TeleCBT-I, Telephone-delivered Cognitive Behavioral Therapy for Insomnia, QOL-CSV, Quality of Life-Cancer Survivor
Version.
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